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The sinoatrial node of the mouse embryo arises from the wall of the right atrium 
near the border of the sinus venosus. Early in development this region expresses the 
transcription factor Tbx5. Because of this, Tbx5 is thought to sit at the apex of a 
transcriptional cascade leading to sinoatrial node (SAN) differentiation. To test this we 
produced a mouse embryonic stem cell line B1 (pTripZ-mTbx5; αMHC::GFP) that 
conditionally overexpresses Tbx5, to determine if this would lead to enhanced SAN 
differentiation. We found that ES cells overexpressing Tbx5 showed enhanced overall 
cardiac differentiation and that cardiac cells showed increased beat rates as compared 
control embryos. Despite this, key genes associated with SAN differentiation including 
HCN4 and Shox2 increased in cells overexpressing Tbx5, while the percent of HCN4 or 
Shox2 positive myocytes did not alter. Faster beating cells showed a decreased expression 
of the chamber specific marker Cx43 and increased expression of Tbx3 and Tbx18. These 
data suggest that Tbx5 overexpression is not sufficient for SAN differentiation, although it 
does activate part of the transcriptional cascade that directs early steps in the SAN. 
Together these data suggest that Tbx5 cannot activate SAN differentiation alone but instead 
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The heart is a large organ containing many cell types, all of which are necessary for 
normal function. Because of this, cardiac regenerative medicine presents many unique 
challenges. Each of the many types of cells within the heart has unique physiological and 
electrophysiological characteristics. Because of this grafts of donor cells must be well 
matched to the area of the heart into which they are grafted to avoid mechanical dysfunction 
or arrhythmia.  In addition, grafted cells must be functionally integrated into the region of 
the graft to effective repair cardiac function. Because of its size and physiological function, 
the metabolic needs of the heart are considerable. Therefore grafts must contain not only 
cardiomyocytes but also a functional vascular network to meet their needs for oxygen and 
nutrition. Here we review progress on the use of pluripotent stem cells as a source for donor 
cardiomyocytes and highlight current unmet needs in the field. We will also examine recent 
tissue engineering approaches integrating cells with various engineered materials that 
should address some of these unmet needs. 
 
Introduction 
Despite the promise of regenerative medicine, cardiovascular disease remains the 
leading cause of death in the United States [1]. Indeed, cardiovascular regenerative 
medicine presents many unique challenges. First, unlike other muscles in the body, the 
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human myocardium possesses only limited cell division [2] and a very limited ability to 
repair itself after injury. A recent study using apical resection of neonatal mouse hearts 
suggested the murine hearts have significant regenerative capacity for some days shortly 
after birth. However, this capacity was lost within the first week of birth and a recent 
attempt to repeat these studies using a different inbred mouse strain showed only 
incomplete regeneration of heart tissue [3]. Together, this suggests that many as yet 
unknown factors may impact the regenerative capacity of the young mouse heart. To date, 
spontaneous regeneration of human hearts, on the scale that would be required to repair a 
typical myocardial infarction (MI), has not been observed. Indeed, it has been suggested 
that a typical infarct episode in the human heart might damage as many as one billion cells 
[4]; well beyond even the most optimistic estimates of the heart's ability to repair itself. 
Recent carbon dating experiments indicate that under normal conditions, cells within the 
adult human are renewed at a rate of about 1% per year until age 25 and at only 0.45% per 
year by age 70 [2], suggesting that there is minimal turnover of cells in healthy hearts. By 
contrast, the heart may be able to activate a program of renewal after injury. One study 
showed significant cell renewal in mouse hearts following pressure overload or infarct [5]; 
however spontaneous functional recovery of adult human hearts after a major cardiac event 
has not been observed. For these reasons, it has long been suggested that the most feasible 
approach to cardiac regeneration after MI would be the engraftment of cardiomyocytes or 
cardiac progenitors that have been expanded ex vivo from stem cell populations. Here we 
will review recent progress in the use of both transcription factor mediated reprogramming 
within the heart and the isolation of cardiac progenitors from pluripotent cells types such 
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as embryonic stem cells (ESCs) and human induced pluripotent stem cells (iPSCs). We 
will also examine how bioengineers are using tissue-engineering approaches that involve 
both cell grafts and hydrogels to improve the integration, differentiation and survival of 
cells to be grafted. 
 
Characteristics of an ideal population for cardiac grafts 
Cells that are useful as potential donors for cardiac repair should be readily 
available, expandable in culture, show an excellent natural ability for self-renewal and have 
contractile and electrophysiological characteristics consistent with their roles within the 
heart. Cells isolated from unrelated donors raise immunological concerns. In addition, the 
use of human ESCs raises ethical concerns. Because of this, non-cardiac contractile cells 
such as skeletal muscle cells and/or non-pluripotent stem cells derived from adult tissues 
were long considered to be the most desirable sources of potential donor cells for cardiac 
repair. More recently, the development of protocols to differentiate large numbers of bona 
fide cardiac cells from iPSCs, have overcome these ethical and immunological concerns 
while raising the hope that these cells may overcome the problems of functional integration 
and arrhythmias. 
In recent years several protocols have been developed for the efficient production 
of cardiac cells from ESCs and these (or slight modifications of these) have proven to be 
equally effective for the differentiation of both mouse and human iPSCs. Most notably, co-
culture of human ESCs (hESCs) with the visceral endoderm-like cell line (END2) [6] has 
been shown to induce 20-25% cardiac differentiation whereas protocols using either 
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carefully timed addition of growth factors [7] or a combination of growth factor addition 
and flow cytometry-based selection of cardiac progenitors [8] have been shown to activate 
30% and 40-50% cardiac cells, respectively. These protocols are in turn based on a large 
body of work, done in frog, chick and mouse embryos, as well as in ESCs to elucidate the 
embryology and molecular genetics of heart induction.  
 
Studies elucidating the molecular mechanisms of cardiac differentiation  
The mammalian heart is made up of cells from at least three sources. First, multi-
potent cardiac progenitors that form during gastrulation give rise to the original linear heart 
tube and are referred to as the first heart field (FHF). In addition to this, two groups of cells 
that lie outside this initial heart tube also contribute to the adult heart. The so-called second 
heart field (SHF) [9-14] and the neural crest [15]. We have previously reviewed the 
embryology and molecular genetics of primary (FHF) heart induction in detail [16, 17]. 
However, a few features that are particularly relevant to stem cell differentiation of cardiac 
cells should be mentioned here. Heart formation is a multistep process that begins with the 
formation of mesoderm during gastrulation. In all vertebrate embryos and in ESCs, the 
activities of Transforming Growth Factor beta (TGFβ) family members and Wnts are 
required for the formation of mesoderm as cells exit the primitive streak (or dorsal lip in 
amphibian embryos) [18-27] . Once formed, the mesoderm immediately begins to migrate 
away from the streak and toward its final position in the embryo where it will begin to 
differentiate according to its location within the embryonic axis [28, 29]. When Wnt signals 
are depleted for the endoderm of early mouse embryos, multiple beating hearts form all 
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along the embryonic axis [30], suggesting that there is a broad potential for cardiac 
formation within the mesoderm of the early embryo. These studies also suggest that Wnt 
signaling from the endoderm appears to actively repress myocardial formation outside of 
the normal heart field. Thus, the migration of mesoderm away from the primitive streak 
may serve, not only to bring cells into their final positions within the embryo but may serve 
to protect the future heart field from Wnt signals that are present in the primitive streak. 
This finding is consistent with earlier studies in chick, frog, mouse and zebrafish 
demonstrating that the transition from uncommitted mesodermal cell to cardiac progenitor 
involves both cell migration away from the primitive streak (or its embryological 
equivalent) and presence of signals that inhibit Wnt [31-33]. In the embryo (and almost 
certainly also in differentiating ESCs), this signal comes from the adjacent endoderm. Later, 
other growth factors including FGF act on the myocardium to activate cell proliferation 
(reviewed in: [16, 17]. Thus a hallmark of FHF induction across all vertebrates is the 
transient activation of Wnt and TGFβ signaling to activate mesoderm formation from the 
pluripotent epiblast, followed by a period of Wnt inhibition that is necessary for 
mesodermal cells to adopt a cardiac fate (Fig 1.1) [34, 35]. As with mammalian embryos, 
a combination of Wnt and TGFβ signaling can be used to activate a primitive streak-like 
activity from ESCs [36] and timely modulation of TGFβ and Wnt signaling have proven 
to be necessary and sufficient to activate the formation of cardiac progenitors and beating 









Fig 1.1 A graphical representation of cardiac differentiation showing the stages of cardiac 
differentiation, including characteristic markers of each stage. Also noted are key 
indicators that differentiate between the first heart field (FHF) and second heart field (SHF). 
Key regulators of each developmental step are indicated. BMP, bone morphogenic protein; 
FGF, fibroblast growth factor; TGF, transforming growth factor. 
  
 7 
Differentiation of SHF cells toward the myocardial state is delayed as they 
proliferate and move toward the heart tube through a mechanism that is not fully 
understood. At about E8.5, SHF cells begin to contribute to the growing heart by migration 
through the arterial and venous poles of the heart. The right and left atria contain derivatives 
from both the FHF and the SHF. By comparison, the left ventricle develops primarily from 
the FHF and the right ventricle and outflow tract (OFT) primarily from SHF progenitors 
[12, 44, 45]. It is unclear whether there is an equivalent to FHF and SHF differentiation 
during cardiomyocyte differentiation from ESC. However, since the major force generating 
cardiomyocytes of the heart (left ventricular cardiomyocytes) are derived from the FHF, 
understanding the factors that mediate the switch between FHF and SHF development may 
lead to improved protocols for the in vitro differentiation of cardiac cells enriched for the 
left ventricular fate. 
 
Cardiac Progenitors 
When embryonic stem cells are differentiated as embryoid bodies (EBs), they 
readily form cardiac cells but they also produce many other cell types. A major area of 
research over the last decade therefore has been the search for markers that could identify 
a cardiac specific progenitor population (Fig 1.1). This would allow researchers to isolate, 
by flow cytometry, just those cells that had the potential to differentiate as myocardial cells. 
Genetic fate-mapping experiments in the mouse indicate that both the FHF and SHF 
are derived from a progenitor population expressing Mesp1. Mesp1 (+) mesoderm emerges 
from the primitive streak of the mouse early during gastrulation (~E6.5) [46, 47] and 
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migrates around the epiblast cylinder, coalescing across the anterior midline to form the 
cardiac crescent at E7.5. By E8.5 the cardiac crescent has undergone a series of 
morphogenetic movement to form the beating linear heart tube. Mice lacking both Mesp1 
and Mesp2 form axial mesoderm at the streak, as assessed by the expression of the pan-
mesodermal marker Brachyury but these mice do not form the migratory "mesodermal 
wings" [48] and as such are devoid of most mesodermal lineages. When ESCs are 
differentiated as embryoid bodies (EBs), typically 2-3% of the cells develop into cardiac 
lineages. When Mesp1 is transiently overexpressed in EBs, this percentage increases to as 
much as 10%, suggesting that Mesp1 expressing cells encompass a cardiac progenitor 
population. However, since most mesodermal lineages are marked early on by the 
expression of Mesp1, this proved to be too non-specific to be an effective marker of cardiac 
progenitors [49].  
Some of the earliest markers of the cardiac primordium are the transcription factors 
Nkx2.5 and Tbx5. Although there is considerable overlap between the expression patterns 
of these two genes, fate mapping reveals that Nkx2.5 is expressed in derivatives of both 
the FHF and SHF [50] whereas the expression of Tbx5 is biased to (but not exclusive to) 
the SHF[51]. Because of this, Nkx2.5 was also examined as a potentially specific marker 
for cardiac progenitors. Nkx2.5 expressing cells that are isolated either in vivo from mouse 
embryos or in vitro from differentiating ESCs are bi-potential and give rise to both cardiac 
and smooth muscle. In addition, this progenitor population can give rise to multiple cardiac 
lineages (based on cell shape and action potential morphology) including atrial, ventricular 
and conduction system [52].  
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At the cardiac crescent and linear heart tube stages, SHF cells, identified by the 
expression of Isl1 [9, 11, 13, 53] and Fgf10 [12], reside outside of the heart tube [11]. Initial 
genetic fate mapping experiments suggested that cells that have expressed Isl-1 give rise 
to both the coronary vasculature and multiple cardiac lineage including cells in the atrium, 
ventricles, conduction system and outflow tract [11, 54, 55], with the majority of cells 
located in the right atrium and outflow tract and only a small contribution to the left 
ventricle [54, 56]. Similarly Isl-1 expressing cells that are isolated from differentiating 
hESCs give rise to smooth muscle, cardiac and endothelial cells [53]. A recent 
reassessment of the Isl1 fate map suggests that Isl1 is expressed in all cardiac progenitors 
[50]. 
One marker that has proven to be extremely useful for the identification and 
isolation of cardiac progenitors is the fetal liver kinase-1 (Flk-1). Flk-1 is the major receptor 
for vascular endothelial growth factor A (VEGF-A). Because this, it was thought that it 
would primarily mark endothelial and hematopoietic lineages. However, Cre-mediate fate 
mapping in mouse embryos revealed, surprisingly, that Flk-1(+) cells also give rise to 
several mesodermal lineages [57, 58] and Flk-1(+) cells isolated from differentiating 
mESCs gave rise not only to endothelial cells but also to cardiac and smooth muscle cells 
[59-61]. Differentiating ES cells that are FACS sorted based on the simultaneous 
expression of both Flk-1 and the chemokine receptor CXCR4 comprise a cardiopoietic 
lineage that is largely depleted of endodermal cell types [62]. Ultimately, the combination 
selection based on Flk-1 (KDR in humans) with addition of pro-cardiogenic growth factors 
proved to be the basis for the very efficient differentiation of cardiac cells from hESCs [8].  
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Unfortunately of the potential cardiac progenitor markers that have been identified 
to date, no single marker identifies cardiac and only cardiac lineages. Therefore the 
isolation of highly purified cardiac cells may require further steps. For example, sorting 
based on the expression of several markers might produce a population that is more 
enriched for cardiac cells or could be used to isolate specific sub-populations within the 
myocardium. Another potential problem with the protocols currently in use to activate heart 
formation from stem cell sources is that they all have the potential to activate the formation 
of multiple cardiac types, including atrial, ventricular and conduction system [63-65], 
raising the possibility of arrhythmias if cells with inappropriate electrophysiologies 
develop within grafts of cells.  
 
Progress and new challenges for cell-based therapies 
This concern is highlighted in recent work by, Murry and colleagues. Their recent 
work highlights the progress that has been made in generating donor cells from ES cells. 
They demonstrated the feasibility of large-scale production of cardiomyocytes from human 
ES cells that can be frozen in sufficient numbers and with sufficient subsequent viability 
for therapeutic applications in humans (1X109 cells). In addition, when these cells were 
injected directly into the infarct zone of a non-human primate MI model, these cells were 
retained within the heart for at least several weeks (and, in the one case that was assessed, 
for up to 3 months) and showed calcium transients that were synchronized with the rest of 
the myocardium suggesting functional engraftment [66]. During these studies, they made 
two observations that highlight the next major challenges for this field. First, although the 
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group size in this study was small, recovery of ventricular function was not statistically 
significant, which raises the possibility that these cells lacked some of the mechanical 
properties of mature ventricular cells. Indeed, myofibril alignment sarcomere registration 
and cardiomyocyte diameter, suggested that these cells were not fully mature. Advances in 
the field on physiological maturation of cardiomyoctyes were recently reviewed in: [67]. 
Electrophysiological maturation was not assessed in these cells, however grafts resulted in 
arrhythmias not observed in sham-injected animals suggesting either incomplete 
electrophysiological maturation or the presence of non-ventricular cardiac cells within the 
graft.  
One of the great unmet needs in the field of cardiac regeneration is to determine the 
extent to which the characteristics of a cardiomyoctye are determined by its final position 
within the heart and what extent is determined by extrinsic factors. In short, when does a 
cardiomyocyte "know" that it will be part of the atrium, ventricle or conduction system? If 
a cell fated for the atrium is grafted into the ventricle what happens to it? Does it change 
its fate according to its new position? Does it die? Does fail to functionally integrate? Or, 
does it become a potential source of arrhythmias? Early fate maps in the chick embryo 
suggest that atrial and ventricular fates within the myocardium are sorted out before they 
exit the primitive streak [68]. This occurs at midblastula in the zebrafish [69]. Explants of 
the prospective chick heart field that are grown in isolation differentiate according to their 
fate. That is, an atrial specific myosin heavy chain is only expressed in posterior explants 
and not in anterior explants that are fated to become the ventricle [70]. Altogether these 
data suggest that some degree of lineage determination has occurred well before cell 
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differentiation as cardiomyocytes. That much said, there is also evidence that the fate of 
cardiac progenitors remains flexible for some time. For example explants of the future 
ventricle could be induced to express atrial markers by treating them with retinoic acid [71] 
and when cells fated to the atrium were grafted into the ventricle, they changed their rate 
of beating [72]. These studies suggested that plasticity was maintained throughout the 
cardiac progenitor phase and only ended after differentiation as beating cardiomyocytes. 
The implication for regenerative medicine is that it may be more therapeutically beneficial 
to transplant cardiac progenitors rather than beating cardiomyocytes. Although, as 
discussed above, we have not yet identified a progenitor population that gives rise 
exclusively to cardiac cells. 
At present few groups have attempted to differentiate cells of specific cardiac 
lineages. The underlying assumption has been that cardiac progenitors function as generic 
cardiac cells that will develop mature electrophysiologies appropriate to their ultimate 
position within the heart. However this hypothesis has not been directly tested. Recently 
[73-75], it has been shown that a small molecule inhibitor of the canonical Wnt/β-catenin 
signaling pathway appears to direct cells with high preference to the ventricular fate. 
Interestingly other small molecule inhibitors of Wnt and the protein Dkk1 do not have this 
effect [74], suggesting that our understanding of the molecular genetics of this process is 
not yet fully understood. The ability to direct myocardial differentiation to specific cardiac 




Transcription Factor-Mediated Reprogramming 
Another area currently being explored for cardiac regenerative medicine is use of 
transcription factor mediated reprogramming of cells. The development of iPSCs [76], 
which demonstrated that essentially any differentiated cell could be restored to a 
pluripotent state by the activation of a small number of transcription factors, renewed 
interest in the concept that any cell might be converted to a different cell type by ectopic 
expression of the correct combination of transcription factors in that cell. Previously, work 
on genes such as MyoD and Pax6, had suggested that at least some cell fates might be 
controlled by single master regulatory genes. Indeed overexpression of the drosophila Pax6 
homolog, eyeless, in legs and wings was sufficient to induce ectopic eye formation [77]. 
Before that, MyoD was shown to be capable of converting fibroblasts to a myogenic state 
[78, 79]. However, further research quickly demonstrated that few, if any, cell fates are 
controlled by the activity of a single master regulatory gene. Current work in the field of 
transcription factor mediated reprogramming has focused on identifying minimal sets of 
transcription factors that might control given cell fates. With regard to the cardiac fate, it 
has been shown that overexpression of three transcription factors (Gata4, Mef2C and Tbx5) 
in mouse fibroblasts or directly in mouse hearts can activate many characteristics of 
cardiomyocytes, including beating, in non-cardiac cells [80, 81]. However attempts to 
repeat this work using tail fibroblasts showed only inefficient reprogramming as well as 
the absence of spontaneous action potentials and contractile phenotype [80, 82]. In addition, 
this combination of transcription factors did not induce full reprogramming in human 
fibroblasts [83]. It may be that a different, or expanded set of transcription factors will be 
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required to accomplish full reprogramming in human fibroblasts. In addition to finding the 
reprogramming factors, the efficiency of this approach will also have to be improved, given 
that the average infarct in humans may involve injury to as many as a billion cells [4]. In 
addition, the current route of delivery of these reprogramming factors in vivo has been 
genetic modification of cells with viruses. This approach may therefore present some 
regulatory barriers. 
Until recently, it has been assumed that reprogramming approaches would involve 
the conversion of a generic cell type, such as a fibroblast, to desired cell types, however, it 
may be possible (and more straight forward) to use transcription factors to convert cells 
from one fate to another closely related fate. For example, Kapoor et al. reported that they 
were able to convert neonatal rat ventricular cardiomyocytes to a pacemaker-like fate by 
transfection of the transcription factor Tbx18 [84].  
These early studies are encouraging but await improvements in efficiency as well 
as studies to determine the extent to which reprogrammed cells recapitulate normal cardiac 
mechanics and electrophysiologies.  
 
Engineering cardiovascular tissues 
Although we have made tremendous progress there are still many challenges for 
cardiac regenerative medicine there are still many challenges that must be solved. Bone 
fide cardiac cells grafted into a non-human primate appeared to be functionally linked to 
the host myocardium, as demonstrated by synchronized calcium transient however the 
caused arrhythmias and did not statistically improve overall ventricular contractility [66]. 
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These findings are possibly due to a failure of these cells to mature in place. In addition, 
thinning of the ventricular was after MI often results in remodel that affects overall heart 
function. Although this was not assessed in Chong et al. remodeling could also contribute 
to the poor recovery of contractile function. 
Solutions for the unmet challenges for cardiovascular regenerative medicine may 
involve the use of engineered materials to enhance cardiac differentiation, 
electrophysiological maturation and/or to preserve or replicate the three dimensional (3D) 
structure of the heart following MI. Here we will specifically focus on the potential of 
hydrogels and the combination of hydrogels with cells in the context of 3-Dimensional (3-
D) printing to meet some of these challenges.  
Using bio-inks or other types of scaffolds, bioengineers are attempting to create 
microenvironments conducive to cardiac differentiation or maturation and/or that maintain 
the 3-D structure of cardiac tissue after MI. Hydrogel scaffolds have also been shown to 
facilitate the growth and expansion of vascular tissues within myocardial grafts. In addition 
to this, by varying the mechanical and chemical properties of hydrogel scaffolds, they can 
be designed in ways that allow researchers to test the roles of mechanical stress [85] or 
electrical pacing (reviewed in: [86]). 
A. Hydrogels 
A number of research groups are now exploring the feasibility of using 
hydrogel/cell combinations as patches or injectable/printable bio-inks. Natural hydrogels 
include Matrigel (a commercially available combination of laminin, TypeIV collagen and 
heparin sulfate) [87], collagen [88], fibrin [89] and alginates [90]. Each of these separately 
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been shown to enhance the retention and integration of injected cells and to preserve the 
normal morphology of the ventricular wall after MI [87]. In addition, a number of synthetic 
hydrogels are being explored [91], however the cytotoxic and immune potential of these 
various synthetic compounds is largely unknown but should be explored. For example 
injection of a non-degradable synthetic polyethylene glycol (PEG) hydrogel into the infarct 
zone of a rat MI model resulted in significant infiltration of macrophages suggesting an 
immune response [92].  
The precise physical properties of hydrogels will likely vary somewhat depending 
on the experimental and therapeutic context, however there are some general 
characteristics that may be highly desirable for use in cardiac regenerative therapies. 
1) The ability to vary the viscosity of a hydrogel would be highly desirable. Lower 
viscosity hydrogels could be injected the wall of a damaged heart with lower injection 
pressure so as to not create further damage to the wall of the heart during injection or cause 
damage to the cells being injected. This would include hydrogels that could be injected in 
a liquid or semi-liquid state but which would become more rigid at body temperature. 
Alternatively, slightly more viscose hydrogels would be useful for 3D printing of organs 
or patches. 
2) For hydrogels that would be injected into heart tissue, it would be desirable to 
have gels with sufficient flexibility so as to not interfere with the contractility of cardiac 
cells within or near the site of the graft.  
3) Temporary hydrogels that could degrade over time could be highly desirable. In 
the short run the gel itself could be used to maintain the geometry of the ventricular wall 
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of the heart during repair. This would give cells encapsulated within the gel time to expand 
and integrate into the host myocardium or provide a scaffold for endogenous stem cells to 
migrate into the infarct zone. 
4) Hydrogels that could be linked through ionic or covalent bonds to peptides or 
proteins that enhance growth, differentiation or physiological function would be 
tremendously useful. Similarly attachment of nano-particles could be used for the delivery 
of drugs in a spatially and temporally controlled fashion. For example, Paul et al. recently 
demonstrated the feasibility of using a hydrogel for localized delivery of the angiogenic 
factor Vegf that was complexed with a functionalized graphene oxide nanosheet[93]. 
B. Hydrogels and Cardiac Repair 
Jonathan Butcher and colleagues recently reported the development of bio-inks 
with high viscosity and low stiffness that were practical for 3D printing of structures that 
encapsulated human aortic valvular interstitial cells (HAVICs). This was accomplished by 
manipulating the relative amounts of methacrylated hyaluronic acid and methacrylated 
gelatin. Increased relative methacrylated gelatin resulted in improved cell spreading and 
maintained fibroblastic phenotype. Using 3D bio-printing they produced 3D tri-leaflet 
valve conduits with hybrid hydrogel encapsulating HAVICs.  
After 7-day of culture, the encapsulated HAVICs showed high cell viability, cell-
type appropriate cell morphologies and expressed all target genes that they tested, including 
αSMA, vimentin, periostin and collagen I [94].  
Pathological remodeling of the ventricular wall is a common and deleterious effect 
of MI. Not only is there thinning of the site of the infarct but the intact wall nearby is also 
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susceptible to dilation that can ultimately lead to heart failure (Fig 1.2). Several groups 
have tested the ability of hydrogels to maintain the geometry of the left ventricular wall 
post-MI. Dobner and colleagues injected 100ul PEG hydrogel or saline into infarct areas 
within 2 minutes of coronary artery ligation. At 2 and 4 weeks after MI, PEG-injected 
hearts had less ventricular wall thinning and significant reduction in end-diastolic diameter 
(EDD) increase. However, after 13 weeks, there was no difference of EDD increase 
between PEG-treated groups with saline-treated [92], suggesting that the impact of this 
hydrogel alone was relatively short lived. Alginates [95, 96], fibrin [97] and collagen [97] 
have also been tested for their ability to moderate ventricular remodeling after infarct with 
similarly positive effects. More recently, hydrogels derived, at least in part from 
decellularized ventricular wall ECM have been used either in sheets as patches [98] or as 
fully injectable fillers to infarct zones [99, 100]. Increasing the percentage of native 
ventricular wall ECM in the injected region facilitated the differentiation of encapsulated 
hESCs-derived cardiac progenitors into differentiated cardiomyocytes, as evaluated by the 
expression of cardiac specific transcription factors, such as cTnT, Cx43 and cTnI. The 
addition of growth factors to hydrogels did not further increase cardiac differentiation 
suggesting the ECM was sufficient to support cardiac differentiation from a progenitor 
population [100]. However, in a similar hybrid hydrogel of ventricular ECM and fibrin, the 
addition of a low dose of TGFβ increased the vascular differentiation of mesenchymal 
progenitor cells [98]. A likely next step would be the use of hydrogel that would include 
both cardiac and vascular progenitor cells with or without the addition of growth factors 
(Fig 1.3).  
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Fig 1.2. A graphical representation of a typical infarcted left ventricle (LV), showing wall 
thinning in the damaged area (yellow). Note that while not thinned, the wall adjacent can 
undergo pathological remodeling that can interfere with normal functioning. 
 
Fig 1.3. A comparison of cell-based therapies for heart repair with a hypothetical 
bioengineering approach. In cell-based therapies cells are injected directly into the infarct 
(yellow). Bioengineering approaches involve injecting cells (or progenitors) of both the 
cardiac and vascular lineages that have been encapsulated or coated on hydrogels. 
Hydrogels have been show to effectively preserve the 3-dimensional structure of the 
ventricular wall after myocardial infarction. They have also been shown to facilitate 
engraftment of donor cells and promote the physiological maturation of engrafted cells. 
Finally, hydrogels can be used for localized delivery of growth factors and drugs. 
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Other approaches used specifically to increase vascular formation within cardiac 
grafts include work by Cui and colleagues who used inkjet printer technology for 2-
dimensional printing of a fibrin scaffold that allows for the growth of vascular structures 
with only minor deformation. After 21 days of culture, the proliferated cells formed a 
tubular microvasculature within the fibrin channels suggesting that thermal inkjet printing 
technology could be used for the bio-fabrication of human microvasculature with high 
resolution [101]. 
On the other hand, Vollert and colleagues, hand fabricated 3D structures with 
micro-channels that served as artificial vessels for the perfusion of engineered heart tissues 
(EHT). To accomplish this, thin alginate fibers were embedded in a matrix of cells, fibrin 
and thrombin. After polymerization the fibers were removed using alginate lyase or sodium 
citrate. These artificial vessels improved the oxygen concentration in the center of the EHT 
and were ultimately populated by endothelial cells [102].  
By combining approaches similar to those described above, Vukadinovic-Nikolic 
et al., recently generated a large sample of EHT. This cardiac construct consisted of three 
separate layers. The bottom layer was decellularized porcine small intestinal submucosa. 
The middle layer was a monolayer of rat neonatal cardiomyocytes and the top layer was 
comprised of rat heart endothelial cells. With this approach, the authors were able to 
engineer an artificial tissue about 11cm2 in size and with an average beat rate of 208±78 
beats/minute on day 3, and 154±48 beats/minute on day 10 as compared to 43±27 
beats/minute only in cardiac cells grown without the other tissues, suggesting that this 
approach may improve the physiological or electrophysiological maturation of cardiac 
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cells. Rat endothelial cells seeded in the top layer cells migrated through the cardiac 
compartment within 7 days and co-localized with the vessel bed of the submucosal 
layer[103]. These studies demonstrate that effects seen by cell engraftment alone can be 
greatly enhanced by using engineering approaches.  
The most ambitious projects in cardiac bioengineering are efforts to completely 
rebuild hearts either by 3D printing or by using decellularized hearts as a scaffold for 
repopulation by cardiac progenitor cells. In 2008, Doris Taylor's lab developed a technique 
to efficiently decellularize rat hearts and subsequently used them as a natural platform to 
fabricate a beating bio-artificial heart. At first, they carried out coronary perfusion with 
SDS over 12h to generate a decellularized construct with a perfusable vascular tree, patent 
valves and intact extracellular matrix (ECM). Then, they reseeded the construct with rat 
neonatal cardiac cells. By day 8, these repopulated structures beat and were able to generate 
a constant albeit weak contractile force (about 2% of the adult heart function)[104]. While 
far from clinical usefulness, this study showed proof of principle that scaffolds of ECM 
could be used to create bio-artificial heart tissue. More recently, Lu and colleagues 
reseeded decellularized mouse hearts with human iPSC-derived cardiovascular progenitors. 
After 26 days of culture, including the addition of growth factors to promote the 
differentiation of cardiac tissue and blood vessel formation, the repopulated hearts showed 
a spontaneous beat rate of 40-50 beats per minute. The beating rate was accelerated to 90 
beats per minute by perfusing isoproterenol. Subsequent studies showed that the perfused 
multipotent cardiac progenitors had differentiated into cardiomyocytes, smooth muscle 
cells and endothelial cells. [105].  
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Heart Conduction System 
The heart functions to supply the embryo with oxygen and nutrition as early as 
embryogenesis [106]. From initial heart formation, the heart generates an electrical impulse 
and propagates this impulse to efficiently pump blood with well-coordinated contractions 
throughout the entire body. In the developing heart, the cardiac conduction system (CCS) 
is made up of several components, each performing a specific function related to regulation 
of heart rate. For instance, SAN generates electrical impulses, which propagates through 
the atrium and reaches the atrioventricular node (AVN). At the AVN the electrical impulse 
is forced to slow down. This delay allows the atria to contract and give rise to filling 
ventricles before the ventricles are activated and contract themselves.  Connective tissue 
formed by the annulus fibrosus isolates electrical signals between the atrial and ventricular 
myocardial tissues. The electric impulse passes from the atrium to the ventricle through the 
atrioventricular bundle (AVB/ bundle of His).  The signal runs through the ventricular 
septal crest, later through the left and right bundle branches (BBs) and the Purkinje fibre 
network. Ventricular conduction system (VCS), activating the ventricular myocardium, 
consists of AVB/His bundle, the BBs and the Purkinje fiber network [106].  
 
Developmental Origin of the Sinoatrial Node 
Vincent Christofells’ lab elucidated the transcriptional program involved in 
sinoatrial node (SAN) differentiation from mesodermal precursors in the mouse embryo 
[106, 107] (Fig 1.4). Tbx5 is at the top of a cascade of transcription factors that direct SAN 
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formation. Tbx5 is expressed in the sinus venosus (SV) and atria throughout cardiac 
development and interacts with Nkx2.5 to regulate several downstream transcription factor, 
including Shox2, Isl1 and Tbx3, key regulators of SAN programming [108, 109]. 
Dominant mutations in Nkx2.5 and TBX5 (Holt–Oram syndrome) cause congenital heart 
defects and AV conduction defects (AV block) [110-112]. Shox2, specifically expressed 
in SV, has an expression pattern complementary to that of Nkx2.5, the TF that activates 
cardiac chamber formation [113]. As a repressor of the Nkx2.5 gene, Shox2 prevents the 
formation of contractile myocardium characteristic of the atrium and ventricle, while 
allowing SAN-specific genes, such as Tbx3 and HCN4 to be expressed [114]. Deletion of 
Shox2 leads to a hypoplastic SV, upregulation of Nkx2.5 and, consequently 
downregulation of HCN4 and Tbx3 in both the SAN primordium of mouse hearts, and in 
ESC-derived cardiac cells [114-116]. With the help of transgenic mice and the 
advancement of lineage tracing techniques, the progenitors of the SAN cells have been 
well established [117]. Mommersteeg and colleagues have demonstrated that around E8, 
the SV develops from Tbx18+/Nkx2.5-/Isl1- progenitors, apart from the rest of the cardiac 
mesoderm. At E8.5, some cells begin to express Isl1, and later at E9.5, a subset within the 
SV starts to express Tbx3, a TF that represses chamber development [118]. Genetic lineage 
tracing has demonstrated that Tbx3+ SAN primordium forms along with the SV between 
E9-9.5 and E11.5-12.5 by adding Tbx18+/Nkx.2.5-/Isl1+ cells to venous pole of the heart 
tube [55, 117, 119, 120]. By E10, the SV and SAN has separated from Nppa+ embryonic 
atrial cells and HCN4 has become restricted to this Tbx3+ domain [121]. Tbx3 is 
continuously expressed during cardiac development, forming the mature heart conduction 
 24 
system, from the SAN to the bundle branches of the ventricular conduction system. Tbx3 
also prevents atrialization by actively repressing genes associated with the working 
myocardium, including αMHC, βMHC, Cx40, Cx43, Scn5a and Nppa/b, (Fig 1.4). Ectopic 
Tbx3 expression leads to the formation of bona fide functional pacemaker cells within these 
atria [121, 122]. Thus Tbx3 directs a pacemaker phenotype in SAN, while Nkx2.5, acting 
in adjacent cells represses Tbx3 and HCN4 allowing development of the atrial myocardium. 
HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel, is initially 
expressed in the first-formed myocytes and immediately activated in Tbx18+/Nkx2.5- SV 
domain and downregulated in Nkx2.5+ myocardium, transferring its expression domain to 
newly-formed SV and the major pacemaker domain [51, 123, 124]. These data suggest that 
pacemaker cells derive from the activation of a particular genetic pathway in cardiac 
progenitors during cardiogenesis. 
Tbx18 is expressed in all SV, including SAN, progenitor cells and in the later-
formed sinus horns and head of the SAN; Tbx18 deficient mice result in a malformed and 
strongly hypoplastic SAN and SV [119, 125]. Tbx18 is required for correct morphogenesis 









Fig 1.4. Proposed model of TF interactions during SAN differentiation. 
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The transcriptional program that directs formation of the AVC and Purkinje system 
The AVC adopts its phenotype through a gene regulatory network, which inhibits 
chamber differentiation, facilitates nodal development, and delimits the strict border 
between the AVC and chamber myocardium [126]. Tbx2 and Tbx3 both play important 
roles in this process. Both Tbx2 and Tbx3 repress the chamber myocardium gene 
regulatory network, such as Nppa, Cx40 and Scn5a. [127-130]. Furthermore, Tbx2 and 
Tbx3 form a positive feedback loop with Bone morphogenetic protein 2 (Bmp2), which 
controls the AVC-restricted expression of Tbx2 and Tbx3 [130]. These T-box factors 
interact with muscle-segment homeobox transcription factor Msx2, suppressing Cx43 
expression directly in the AVC [131, 132]. They also compete with Tbx5 for binding to T-
box elements in target genes including Nppa and Cx40 [133], and for interaction with 
Nkx2.5 to inhibit Nppa in the AVC [134].  
The Purkinje fiber network is found only in mammals and birds, which arises from 
the trabecular myocardium. The embryonic ventricles are mainly composed of trabecular 
myocardium during embryogenesis, acting as both the functional and cellular precursor of 
the Purkinje fiber network [135]. Elegant clonal and lineage analyses showed the 
spatiotemporal expression pattern of Cx40 [136, 137]. When Cx40+ cells were irreversibly 
labeled at E10.5, labeled descendants were observed both in the Purkinje fibers and in the 
Cx40- negative compact wall. However, when Cx40+ cells were labeled at E16.5, the 
Cx40+ trabecular zone had become a relative small population and labeled Cx40 
descendants were only found in Purkinje network, indicating the lineages of Purkinje fibers 
and ventricular myocardium separated between E10.5 and E16.5.  
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Sinoatrial Node arrhythmias 
In the adult human heart, the sinoatrial node (SAN) is crescent-shaped structure 1 
to 2 cm long and 0.5 cm wide, that lies at the junction of the superior vena cava with right 
atrium and locates along the sulcus terminalis. The SAN itself consists of clusters of 
pacemaker cells organized in parallel rows with thin digitations. The SAN arrhythmias is 
referred to a clinical syndrome including SAN dysfunction, frequently depressed escape 
pacemaker, and atrioventricular nodal conduction disturbance. SAN arrhythmias describes 
a series of abnormalities, leading to complicated sinus bradycardia, sinus arrest, sinus 
pauses, SAN exit block, which is defined as inefficient and inappropriate response to 
physiological demands during exercise [138]. 
  
Conclusions 
Work by Chong et al. [66] highlights the advances that have been made in cardiac 
regenerative medicines based on cell-based therapies alone. However these studies also 
highlight the unique challenges presented by this field. Here we highlight several recent 
studies that demonstrate the potential power of combining cells with engineered materials 
(Fig 1.3). These studies suggest that encapsulating cardiac or cardiac progenitor cells 
within hydrogels may greatly enhance their regenerative capacities. This is accomplished 
by providing scaffolds that facilitate migration and differentiation, mechanically protect 







The overall goal of this research is to understand the mechanisms underlying the 
differentiation of the SAN. To study this I have used mouse embryonic stem cells, 
differentiated as EBs.  Vincent Christofells’ lab has identified a number of transcription 
factors that are necessary for differentiation of the SAN in mouse embryos.  It is not yet 
clear if these factors are sufficient for SAN differentiation. To test this I mad lentiviruses 
to conditional overexpress these genes. At the top of this transcriptional cascade is the 
transcription factor Tbx5. Tbx5 has been shown to activate expression of Shox2, Tbx3 and 
Islet1.  I made viruses to express all of these factors and also carried out detailed analysis 
of Tbx5.  In addition to this, the Foley identified TAK1/Map3k7 as an important factor that 
can activate Tbx5 and this entire transcription pathway.  I also made a virus to conditionally 
overexpress TAK1 and analyzed gene expression in a previous isolated TAK1 
overexpressing cell line. Finally, I found that gene expression analysis within a EBs was 
complicated and that overall changes in genes sometimes masked gene changes specifically 
in cardiomyocytes, so I began to develop a technique to examine gene changes specifically 






Specific Aim 1: To study the role of Tbx5 overexpression in mouse embryonic stem 
cells-derived cardiomyocytes and determine if it is sufficient to drive SAN 
differentiation. 
The goal of Specific Aim 1 is to test if overexpression of Tbx5 during EB 
differentiation is sufficient for SAN fate. In chapter 4, we will examine the role of Tbx5 in 
differentiation of the sinoatrial node (SAN) from mouse embryonic stem cells. The SAN 
of the mouse embryo arises from the wall of the right atrium near the border of the sinus 
venosus. Early in development this region expresses the transcription factor Tbx5. Because 
of this, Tbx5 is thought to sit at the apex of a transcriptional cascade leading to SAN 
differentiation. To test this we produced a mouse embryonic stem cell line B1 (pTripZ-
mTbx5; αMHC::GFP) that conditionally overexpresses Tbx5 under the control of a 
Doxycycline inducible promoter. 
We differentiated mESCs into EBs at Day 0 (D0) by using hanging drop method 
(around 300 cells per 20 µL drop) described in [139, 140]. After 24 hours (D1), EBs were 
washed off and plated on gelatin-coated plates for EB differentiation. We treated these EBs 
with 200ng/ml Dox from D4. By D15, D17 and D21, we recorded the 20-seconds-long 
videos with beating area (identified based on the expression of αMHC::GFP) to measure 
beat frequencies. Changes in mean intensity within regions of interests in phase contrast 
image sequences serve to detect motion indicative of cellular contractions, and beat 
frequencies are extracted using a MATLAB algorithm that first performs a non-linear 
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normalization (to account for non-specific large scale movements), followed by a fast 
fourier transformation of the data, which corrects for pausing of beating during imaging. 
Differentiated EBs were treated with 200ng/ml Dox from D4. Then at D19 and D21, 
EBs were dissociated into single cell suspension by trypsin digestion and replated onto 
chamber slides. Immunocytochemistry staining was used to distinguish the cardiac subtype 
among all cardiomyocytes, such as HCN4, Shox2 for pacemaker-like myocytes; Cx43 for 
ventricular-like myocytes; GFP, DsRed and CT3 for marking all cardiomyocytes. The 
percentage of HCN4, Shox2 and Cx43 positive myocytes were measured to display the 
overall subtype characteristic of myocytes. 
Activation of the SAN transcriptional program will be assayed by qRT-PCR. 
Differentiated pacemaker cells are expected to express high levels of genes involved in 
SAN development (Tbx3, Tbx5, Shox2, Isl1, HCN4) and low levels of ventricular genes 
(Cx43, Nkx2.5). At the meantime, MAP3K7/TAK1 mRNA level was measured between 
R1, B1 untreated and B1 Dox-treated EBs. 
 
Specific Aim 2: To determine the effect of MAP3K7/TAK1 overexpression during EB 
differentitation on early lineage differentiation. 
The goal of Specific Aim 2 is to determine how MAP3K7/TAK1 kinase affects 
SAN differentiation but also how it impacts the formation of early endodermal and neural 
markers. In chapter 5, I analyzed MAP3K7/TAK1 overexpressing EBs using qRT-PCR 
analyses and FACS data, comparing wild type EBs to MAP3K7-overexpressing EBs.  I 
analyzed both pacemaker genes and genes expressed in other lineages relevant to heart 
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induction, specifically visceral endoderm (VE), anterior visceral endoderm (AVE) and 
definitive endoderm (DE). In addition I examined expression of genes related to Sonic 
Hedgehog (Shh) signaling and early neural induction.  
 
Specific Aim 3: To develop a protocol for the single cell analysis of gene expression 
during myocardial differentiation 
The goal of Specific Aim 3 is to figure out gene expression by single cell analysis 
during cardiac differentiation. In chapter 6, I will examine the expression of SAN and other 
cardiac markers specifically in cardiomyocytes. In all of these studies we are examining 
gene expression in whole EBs and examining markers that are expressed in the heart and 
endoderm but are also often expressed in other non-cardiac, non-endoderm lineages.  
Therefore it is sometimes difficult to know whether observed changes are due only changes 
in the cardiac (or endodermal lineage). To address this we have begun to develop a 
technique that will allow us to examine gene expression in just the cardiac lineage.  Briefly, 
ES cells harboring the αMHC::GFP promoter reporter are differentiated until day 21 and 
cardiomyocytes isolated by flow cytometry.  From these cells we isolated RNA and then 
carried out real time PCR for genes expected to be expressed in cardiomyocytes.  A number 
of technical challenges remain to be addressed with this protocol. These data represent 
promising preliminary data for a new, more accurate assessment of cardiac differentiation 
in our assay system. 
 
Specific Aim 4: Design and verify cell lines overexpressing SAN genes 
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The goal of Specific Aim 4 is to test the effect of overexpression of SAN specific 
genes other than Tbx5 during EB differentiation. In Chapter 7, I will show data verifying 
gene overexpression in both the Tbx5 and other overexpression cell lines. Vincent 
Christofells has described a transcriptional hierarchy that directs the differentiation if 
sinoatrial node cells in the mouse embryo. The major transcription factors involved are: 
Tbx3, Isl1, Shox2, Tbx18 and MAP3K7/TAK1 [107, 141].  To study their function in 
directing SAN differentiation I made ES cell lines that will allow me to conditionally 
overexpress these factors. One of these lines (B1, which overexpressed Tbx5) is described 





MATERIAL AND METHODS 
 
Cell Culture 
Mouse embryonic stem cells (mESCs) were cultured in 10 cm tissue culture dishes, 
covered with 10 ml high glucose Dulbecco’s Modified Eagles Medium (DMEM) with 10% 
ES-Qualified Fetal Bovine Serum (FBS), 1% penicillin-streptomycin, 1% L-glutamine, 1% 
non-essential amino acids, 1% sodium pyruvate, 0.1 mM 2-mercaptoethanol and 1000 U 
per ml LIF.  
293T cells were culture in 10 cm tissue culture dish, covered with 10ml DMEM 
with 10% FBS, 1% penicillin-streptomycin, 1% L-glutamine and 1% Sodium pyruvate. 
 
Plasmid transfection and Lentivirus production 
Before plasmid transfection, cell medium of 293T (60-80% confluent) were 
removed and replaced with 11 ml standard culture medium supplemented with 20% FBS. 
Virus were produced using the second generation lentiviral system according to the 
protocol [142]. Plasmids were combined as follows: 30 µg (30 µl) transfer vector, 20 µg 
(20µl) p8.74, 10 µg (10µl) pVSV-g and 1290 µl H20 (total volume 1350µl). Note: from 
this point on, consider this to be “live virus” in terms of safety precautions, for example, 
wear double gloves, lab coat and disposable sleeve protectors. Do not aspirate solutions 
but pipet them into bleach so that the final concentration is at least 10%.  All pipets and 
other plastic ware should also be washed in bleach for 10 minutes before discarding.  Hood 
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and all equipment should be “UV” irradiated for 10 minutes after you are done.  Any drops 
of viral-containing solutions should be wiped up immediately. Additional 150 µl CaCl2-
dropwise was added using a 200 µl pipetman very slowly and gently with constant 
vortexing (1800rpm, medium strength), following 1500 µl of Hank's balanced salt solution 
(HBSS) dropwise slowly. The mixed solution will form complexes in about 20 minutes. 
Cultures should not be disturbed at this time. The mix solution was added to the 293T cells 
dropwise using a 2ml pipetman. Try not to disturb the plates when transferring them back 
to the incubator. Next day cell medium were switched to 25 ml Lonza Ultraculture Medium, 
plus 1% penicillin-streptomycin and 2% L-glutamine. Ultraculture medium were collected 
every day for three days. On the last day, these medium were ultracentrifuged in swing 
bucket rotor SW28 at 20,000 rpm for 2 1/2 hours (These would take a total of 4 hours 
almost to complete run). Finally, supernatant was carefully removed and the virus pellets 
were resuspended within 400-600 µl remaining medium. Then the viruses were aliquoted 
and stored at -80C. 
 
Lentivirus Transduction and establishment of clonal cell lines. 
Multiplicity of Infection (MOI): Multiplicity of Infection is the number of 
transducing lentiviral particles per cell. Typically, 5000 cells are used for infection and 
MOI rate are set up at 10, 20, 40; this needs lentivirus package for 50000, 100000 and 
200000, respectively. At first, dissociated mESCs were mixed with lentivirus packages at 
MOI 10, 20 and 40, plus 10 µg/ml polybrene and incubated at 37C for an hour with gentle 
re-suspension every 15 minutes.  Mix solution was replated onto 24 well pre-coated plate.  
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Fresh medium was added after 24 hours and 1 µg/ml puromycin selection media was added 
after 48 hour. After 2-3 days of puromycin selection, cells were trypsinized and replated 
onto 96 well plate for one cell per well. Continuous monitor for a couple of days, potential 
mouse embryonic stem cell colonies grown from single cell clone were expanded and then 
analyzed for doxycycline treatment later. 
 
Embryoid Body (EB) Differentiation 
mESCs were differentiated in standard differentiation medium, which contains 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% differentiation-
tested FBS, 5% protein-free Hybridoma Media (PFHM-II), 1% penicillin-streptomycin, 
0.5 mM L-ascorbic acid, 0.45 mM monothioglycerol and 200 µg/ml apo-Transferrin. 
Embryoid Bodies (EBs) were formed into 20 µl hanging drop, which consists of 300 cells 
and then incubated at 37C for 24 hours. After 24 hours, EBs were gently washed with petri 
dish pre-coated with 0.1% gelation, as marked as “Day 1”. 
 
Construct of pTripZ Vector, doxycycline-inducible-Gene of Interest (GOI)-
overexpression Vector 
The open reading frame of different GOI, including mTbx5, mTbx3, hIsl1, hShox2, 
hTbx18 and mouse MAP3K7 was amplified by PCR and directly cloned into downstream 
of TurboRFP motif into the pTripZ vector (purchased from Add gene), which drives 
expression of TurboRFP and the insert GOI with administration of Doxycycline. 
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Lentiviruses were produced using the second-generation lentiviral expression system 
(Table 3.1). 
 
Construct of pTET-ON Vector, doxycycline-inducible-GOI-overexpression Vector 
The open reading frame of different GOI, including mTbx5, mTbx3, hIsl1, hShox2, 
hTbx18 and mouse MAP3K7 was amplified by PCR and directly cloned into downstream 
of pTight TET-Responnsive promoter into the pTET-ON vector (purchased from Add 
gene), which drives expression of the insert GOI with administration of Doxycycline. 
Transfection of target vector into mESCs was used to generate GOI-overexpression mouse 
ES cell line (Table 3.2). 
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Table 3.1. GOI Primer was used to clone into downstream of TurboRFP motif into the 
pTripZ vector. 

























Table 3.2. GOI Primer was used to clone into downstream of pTight TET-Responnsive 
promoter into the pTET-ON vector. 
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List of vectors and mESCs line made 
Here is the detailed list of all vectors and mESCs made in Foley lab (Table 3.3).  
No Vector Insert Gene mESCs  
1 pTripZ mTbx5 B1, B5, B10, B12 
2 pTripZ mTbx3 X1, X6, X13 
3 pTripZ hIsl1 I4 
4 pTripZ hShox2 S2 
5 pTripZ hTbx18 T2 
6 pTripZ MAP3K7 M8 
7 pTET-ON mTbx5 DB4, DB6 
8 pTET-ON mTbx3 DX5, DX9 
9 pTET-ON hIsl1 DI1, DI2, DI3, DI7 
10 pTET-ON hShox2 DS13, DS14 
11 pTET-ON hTbx18 DT2, DT5 
12 pTET-ON MAP3K7 DM11 
 




EBs were collected on specific days of differentiation, such as D5, D7 and so on. 
Total RNA was extracted with RNeasy Mini Kit (Qiagen, cat#74106), and 1 µg was used 
to synthesize the first strand cDNA using QuantiTect Reverse Transcritption Kit (Qiagen, 
cat#205313). Quantitative PCRs were performed with SybrGreen Master Mix (Roche, cat# 
3752186001), using 40 ng template/reaction on a Roche LightCycler® 480 Real-Time 
PCR Instrument, and analyzed with the LightCycler 480 software package (version 1.5.0 
SP1). Crossing point data were first adjusted to reflect the efficiency of primer pairs by 
comparison to standard curves (based on dilution series over a total dynamic range of 
1:1,000 or 1:10,000 for positive control cDNAs) and subsequently normalized to the 
ubiquitously expressed transcript GAPDH. Data represent averages ± standard error of 3 
independent experiments. Further analyses were using GraphPad Prism (version 7.0). 
Primers used in this study are as follows:  
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GAPDH AATGGATACGGCTACAGC GTGCAGCGAACTTTATTG 
HCN4 
ACC TGA CGA TGC TGT TGC TG 
CTC TGC GGG TCA AGG 
ATG AT 
m/h Isl1 GGTTGTACGGGATCAAAT GAGCGGGCACGCATCACG 
m/h Shox2 ACC AAT TTT ACC CTG GAA 
CAA C 











GTT TTG TCT GGG AGG GAG CA 
CTT CAG CCC CGA CTT 
CCA TA 
Tbx5 CCA GCT CGG CGA AGG GAT 
GTT T 
CCG ACG CCG TGT ACC 












































Table 3.4. qRT-PCR primers of Cx30.2, Cx43, GAPDH, HCN4, m/h Isl1, m/h Shox2, m/h 
Tbx18, MAP3K7, Tbx3, Tbx5, mCXCR4, mGPC1, mTm4sf2, mSox17, mSox2, mDkk1, 





EBs were treated with 0.25% Trypsin/EDTA at 37C for 30 minutes and then 
neutralized with regular differentiation medium. Cells were centrifuged at 2000 rpm for 5 
minutes and resuspended with fluorescence-activated cell sorter (FACS) buffer (PBS plus 
1% BSA and 10 ng/ml DNAse). Then cells were centrifuged again and resuspended with 
FACS buffer. Cells were filtered through a 100µm sieve and cell numbers were counted 
using a haemocytometer, checking single cell suspension at the same time. Flow cytometry 
was performed with the Beckman Coulter MoFlo Astrios EQ cell sorter and data was 
analyzed using FlowJo VX software.  
 
Immunocytochemistry 
EB dissociation was performed as decribed above for Flow Cytometry. Around 
55000 cells with the property of single cell suspension were replated onto 4 well Lab-Tek 
II chamber slide (Nunc, cat#154526), pre-coated with 0.1% gelation and then incubated 
within standard differentiation medium at 37C overnight to allow dissociated cells to attach 
and spread. Cells were fixed at 4% PFA for 15 minutes and gently washed with PBS 3 
times for 5 minutes. Then cells were block with either cytosol antibody staining buffer 
(CASB) or nuclear antibody staining buffer (NASB) for an hour, depending on subcellular 
location of target protein expression. CASB is consist of PBS, 1% FBS, 0.1% BSA and 
0.1% Triton-X-100; while NASB contains PBS supplemented with 1% FBS, 0.2% BSA 
and 0.25% Triton-X-100 for nuclear membrane penetration. Cells were incubated with 
primary antibody diluted within either CASB or NASB overnight. Cells were washed with 
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PBS 3 times for 5 minutes and then incubated with Alexa Fluor-labelled secondary 
antibody for an hour. Additional PBS wash was performed and at the last wash DAPI was 
added into PBS buffer for 5 minutes incubation. Finally, chamber slides were mounted 
with special fluorescence mounting media and sealed with clear nail polish. Later, images 
were taken on Zeiss AxioImager microscopy. The primary antibodies were used as follow: 
Cx43 (Sigma, cat#C6219, 1:1000), CT3 (DSHB, cat#CT3, 1:250), DsRed (Clontech, 
cat#632392, 1:500), GFP (Thermo, cat#A11122, 1:500), HCN4 (Sigma, cat#SAB520035, 
1:250), Shox2 (abcam, cat#ab55740, 1:1000), Tbx5 (Thermo, cat#42-6500, 1:500). 
 
Beat Rate data 
During EB differentiation, we will use live cell imaging of beating cardiomyocytes 
(identified based on the expression of αMHC::GFP) to measure beat frequencies. Changes 
in mean intensity within regions of interests (ROI) in phase contrast image sequences serve 
to detect motion indicative of cellular contractions, and beat frequencies are extracted using 
a MATLAB algorithm that first performs a non-linear normalization (to account for non-
specific large scale movements), followed by a fast fourier transformation of the data, 




TBX5 OVEREXPRESSION ENHANCES CARDIAC DIFFERENTIATION AND 
INCREASES BEAT RATE BUT DOES NOT INCREASE THE FORMATION OF 
FULLY DIFFERENTIATED SINOATRIAL NODE CELLS 
 
Introduction 
The Sinoatrial Node (SAN), as the primary pacemaker of the mammalian heart and 
controls heart rate throughout the life of all mammals. Failure of SAN function leads to 
slow heart rate (bradycardia) and inefficient circulation of blood flow. Bradycardia may be 
due to congenital disease or heart attack. Currently, the sole treatment for bradycardia is 
implantation of electronic pacemakers and there are several complications including, 
surgical complication, battery life issues and lead displacement. That’s the reason why we 
need a biological pacemaker. Producing a biological pacemaker in vitro would result in an 
alternative pacemaker therapy in which replacing the failing SAN with a new biological 
one would become practical through cell transplantation. My project is to determine 
whether a biological pacemaker can be produced by direct reprogramming of cells to the 
SAN fate. Specifically I will address whether forced overexpression of the SAN specific 
gene, Tbx5. can accomplish this. 
 
Four independent clonal lines that conditionally overexpress Tbx5 were established. 
To test the role of Tbx5 in SAN development, mouse embryonic stem cell (mESC) 
lines were generated to conditionally overexpress Tbx5. To do this, the open reading frame 
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of Tbx5 was cloned downstream of the TurboRFP motif into the pTripZ vector.  This was 
used to generate lentivirus in which genes of interest (GOI) can be overexpressed by the 
administration of doxycycline (Fig 4.1A). 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation.  At the top of this cascade is Tbx5. Genetic studies in 
mouse have revealed an essential role for Tbx5 in establishing the SAN however, it has not 
been shown whether Tbx5 is sufficient for SAN differentiation.  To study its role we 
established four independent, clonal ESC lines (B1, B5, B10 and B12), all of which showed 
stable, inducible, upregulation of Tbx5 transcripts, as confirmed by qRT-PCR at 24, 48 and 
72 hours after addition of 1 µg /mL doxycycline  (Fig 4.1B). 
Immunocytochemistry using the anti-Tbx5 antibody was performed to confirm that 
doxycycline also activated Tbx5 protein formation (Fig 4.1C). We found within colonies 
of ES cells Tbx5 expression in nuclei.  
Together these data confirm that four separate ES cell lines were generated that 
overexpressed Tbx5 in both transcripts and protein level in response to doxycycline. 
 46 
 
Fig 4.1. Verification of B1 pTripZ-mTbx5; αMHC::GFP mouse embryonic stem cell line. 
Fig 4.1A. Schematic design of pTripZ-mTbx5 Vector, doxycycline-inducible-Tbx5-
overexpression backbone. Fig 4.1B. B1, B5, B10, B12 mESCs were treated with 
doxycycline at 1000ng/ml and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Tbx5. Fig 4.1C. B1 mESCs were treated with 
doxycyline at 200ng/ml for 48h or untreated, and then immunostained the anti-Tbx5 
antibody to detect nuclear expression of this protein. Scale bar, 20 µm. Data represent 
means ± standard error of 3 independent experiments. Statistical significance was 
determined by unpaired, two-tailed t-test. **p<0.01, ***p<0.001 
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Addition of Doxycycline increased beat rate 
One indication that cardiac cells have adopted the SAN identity, is an increased rate 
of beating.   To determine if our mESCs differentiate as SAN cells in response to increased 
expression of Tbx5, mESCs were differentiated as EBs and doxycycline added from Day 
2 until either day 15 or Day 20 at which point beat rate was assessed. B1, B5 and B10 EBs 
were tested for increased beat rate with working dose curve of doxycycline. Beating areas 
were identified based on visual inspection and confirmed by expression of αMHC::GFP 
which we previously showed was a faithful reporter of cardiac differentiation [141]. Beat 
was manually calculated but visual inspection, counting beats/minute.  
Lines B5 and B10 showed a modest increase in beat rate at 100 ng/ml.  Line B1 
showed significant increase in beat rate at 100ng/ml, 200ng/ml and 500ng/ml. However 
the greatest increase in beat rate was observed at 200ng/mL (Fig 4.2A). For this reason, 
line B1 and a dose of 200 mg/ml doxycycline were used for all subsequent evaluation. 
We previously showed that MAP3K7 overexpressing cells that later adopted a 
sinoatrial node fate began to beat quickly around Day 15 of EB differentiation [141]. To 
test this, beat rate was also collected and analyzed at Day 15.  We found that beat rate was 
also significantly increased at day 15 at 100ng/ml, 200 ng/ml and 500ng/ml.   
Manual counting of beat rates is subject to interpretation and cannot always account 
for pausing of EBs; in addition, beats greater than 100 beats per minute are very difficult 
to count manually with great accuracy. We previously developed a MATLAB automation 
to calculate cardiac beats from movie clips based on changes of pixel density at the edges 
of beating areas [143].  To determine how well this software compares to manual count, 
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beating data were recalculated for the B1 line at Day 15, 17 and 21 using the automation. 
This also allowed us to check all beating areas accurately (Fig 4.2B).  At Day 15, both B1 
and B1 dox showed increasing rate of beating as compared to cardiomyocytes from EBs 
differentiated from the parent cell line R1 αMHC::GFP (R1). However, B1 treated with 
doxycycline did not beat faster than untreated B1 cells until Day 17 in this assay (Fig 4.2C). 
At D21, B1 Dox-treated beat faster than both B1 and R1 cells, while B1 and R1 had no 
significant difference.   
All these beat data confirms that administration of dox to B1 does increase beat rate 



















Fig 4.2. Manual beat data and automatic beat data. Fig 4.2A. Manual beat data counting of 
B1, B5 and B10 EBs at Day 20 with Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 
100ng/ml, 200ng/ml and 500ng/ml. Fig 4.2B. Manual beat data counting of B1 EBs at Day 
15 with indicated dose of doxycycline treatment. Fig 4.2C. Using MATLAB automation 
to calculate cardiac beats of R1, B1 and B1 Dox-treated EBs at Day 15, Day 17 and Day 
21. Data represent means ± standard error of 3 independent experiments. Statistical 
significance was determined by one-way ANOVA (Fig 3.2A&3.2B) or unpaired, two-




Relative Tbx5 RNA Expression during EB differentiation 
Although addition of Dox worked well in B1 mESCs, yet regulation of gene 
expression within differentiating EBs is much more complicated. To test whether addition 
of Dox also upregulated Tbx5 transcripts during EB differentiation, EBs were collected 
from Day 5 to Day 21 and assessed Tbx5 transcription by qRT-PCR (Fig 4.3). Interestingly, 
both B1 and B1 dox showed higher levels of Tbx5 than the parent cell line R1. Doxycycline 
treatment did also result in statistically significant increases of Tbx5 at Day 15 and Day19, 
but not at all days of differentiation. In fact, by Day 21, when we saw increased beat rates, 
dox-treated cells had lower levels of Tbx5 transcripts. This suggests: 1) regulation of 
transcriptions within EBs is highly complex and dox-inducible transcripts may not be able 
to activate sufficiently high levels of expression to overcome normal changes in gene 
expression that occur during EB differentiation; 2) The B1 line either due to leakiness of 
the construct or due to gene insertion effects has naturally higher levels of Tbx5 expression 
as compared to the parent cell line (R1); 3) at Day 21 increased beat rate cannot be due to 
active transcription of Tbx5. Besides B1, B5 and B10 EBs treated with Dox compared to 
untreated EBs were tested for regulation of Tbx5 (Fig 4.4). EBs were treated with Dox 
from Day 2 to Day 11 and collected for later qRT-PCR analysis. As shown in Fig 4.4, both 
B5 and B10 EBs treated with Dox did not increase Tbx5 transcripts.   
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Fig 4.3. Relative Tbx5 expression during EB differetiation. EBs were collected from Day 
5 to Day 21 and assessed Tbx5 transcription by qRT-PCR between B1 and B1 Dox-treated 
EBs (Fig 4.3A), R1 and B1 EBs (Fig 4.3B) or R1 and B1 Dox EBs (Fig 4.3C). Data 
represent means ± standard error of 3 independent experiments. Statistical significance was 





Fig 4.4. Relative Tbx5 expression during B5 and B10 EB differetiation. EBs were collected 
from Day 1 to Day 11 and assessed Tbx5 transcription by qRT-PCR among R1, B5 and B5 
Dox-treated EBs (Fig 4.4A) or among R1, B10 and B10 Dox-treated EBs (Fig 4.4B). Data 
represent means ± standard error of one independent experiment.  
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One possible explanation for increased expression of Tbx5 in the absence of dox 
would be the presence of tetracycline (TET) in the serum (FBS #A87F82H).  To test this, 
one experiment was repeated with EBs grown in TET-free medium (TET-free FBS 
#AC10251184).  Tbx5 expression in B1 EBs was not decreased when cells were grown in 
Tet-free media (Fig 4.5A). Next, another experiment was repeated again with R1 EBs 
grown in TET-free medium versus normal medium. The relative Tbx5 expression of R1 
αMHC::GFP EBs grown in TET-free media only increased at Day 9 compared to normal 
medium (Fig 4.5B). Then two more analysis were done with between R1 and B1 EBs either 
with TET-free medium or normal medium (Fig 4.5C&D). In Fig 4.5D, increased Tbx5 
expression was observed with the same pattern as Fig 4.5A. As concerned, we decided to 








Fig 4.5. B1 or R1 EBs were cultured in standard differentiation medium with either FBS 
#A87F82H or TET-free FBS #AC10251184. EBs from D1 to D9 were collected and 
relative Tbx5 level was analyzed by qRT-PCR. Data represent means ± standard error of 3 
independent experiments. Statistical significance was determined by unpaired, two-tailed 




Tbx5 overexpression increases overall cardiac formation 
Tbx5 is a key player in cardiac development. Since B1 naturally expresses higher 
levels of Tbx5, it should also be more active in cardiogenesis. To test this, EBs were 
differentiated with or without the addition of dox from Day 2 to Day 21 (Fig 4.6A) or from 
Day 4 to Day 21 (Fig 4.6B). Cells were isolated at Days 17, 19 and 21. The percentage of 
cardiac differentiation was assessed based on expression of GFP by flow cytometry. In all 
cases, more cardiac cells formed from B1 cells but addition of Dox never enhanced cardiac 
differentiation further. 
In another study, the goal is to figure out whether administration of doxycycline 
increases R1 parent cell line’s cardiac differentiation. EBs were differentiated with or 
without the addition of dox from Day 4 to Day 21 (Fig 4.7). Dissociated EBs were analyzed 
by flow cytometry at Day 19 and Day 21.  Expression of GFP recognized the percentage 
of cardiac differentiation by flow cytometry. At Day 19 and Day 21, addition of 
doxycycline did not increase the cardiac cells formed from R1 αMHC::GFP cells, while 












Fig 4.6. Cardiac differentiation analyzed by Flow Cytometry.  EBs were differentiated with 
or without the addition of Doxycycline from Day 2 to Day 21 (Fig 4.6A) and from Day 4 
to Day 21 (Fig 4.6B). The percentage of cardiomyocytes was determined by Flow 
Cytometry Data represent means ± standard error of 3 independent experiments. Statistical 










Fig 4.7. Cardiac differentiation analyzed by Flow Cytometry at Day 19 and Day 21.  EBs 
were differentiated with or without the addition of Doxycycline from Day 21. The 
percentage of cardiomyocytes was determined by Flow Cytometry Data represent means 
± standard error of 3 independent experiments. Statistical significance was determined by 




Subtype of Differentiated Cardiomyocytes  
Immunocytochemistry (ICC) staining is current standard to figure out cardiac 
subtype based on protein expression, such as HCN4 and Shox2 for pacemaker marker or 
Cx43 for ventricular marker. Here four different EBs including R1, MAP3K7/TAK1-
overexpressing EBs (pgk:MAP3K7/TAK1; αMHC:mCherry) [141], B1 untreated, B1 
Dox-treated were analyzed for HCN4, Shox2 and Cx43 positive cardiomyocytes (Fig 4.8A). 
MAP3K7/TAK1-overexpressing EBs had more HCH4 and Shox2 positive cardiomyocytes 
than R1 EBs, however there was no significant difference either between R1 and B1, or 
between B1 and B1 dox-treated EBs. Meanwhile, MAP3K7/TAK1-overexpressing EBs 
had less Cx43 positive cardiomyocytes than R1, while B1 and B1 dox-treated EBs also had 
less Cx43 positive cardiac cells than R1 EBs. B1 Dox-treated EBs had less Cx43 positive 
cardiomyocytes compared to B1 untreated EBs. 
At the same time, whole EBs from R1, B1 and B1 dox-treated group were collected 
and later assessed by qRT-PCR at Day 21 (Fig 4.8B). All transcripts data were normalized 
to B1 untreated EBs, each trials normalized. MAP3K7/TAK1 transcripts did not change 
among three groups. Tbx5 as previous described, B1 dox-treated EBs and R1 EBs had 
significant less Tbx5 transcripts. Compared to R1 EBs, B1 EBs had more Shox2, Tbx3, 
Tbx18, HCN4 and Isl1, theses downstream pacemaker marker of Vincent Christofells 
models. There was no significant difference between B1 and B1 Dox-treated EBs, while 
B1 Dox-treated showed the similar expression pattern. However, B1 EBs activated Nkx2.5 
expression compared to R1 EBs. 
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In parallel, the same experiments described above were performed again to figure 
out the subtype of cardiomyocytes at Day 19 (Fig 4.9). MAP3K7/TAK1-overexpressing 
EBs had more HCN4 and Shox2 positive cardiomyocytes than R1 EBs, however there was 
no significant difference either between R1 and B1, or between B1 and B1 dox-treated EBs. 
Meanwhile, MAP3K7/TAK1-overexpressing EBs had less Cx43 positive cardiomyocytes 
than R1, while B1 and B1 dox-treated EBs also had the similar level of Cx43 positive 
cardiac cells compared to R1 EBs (Fig 4.9A).  For all markers at Day 19, there was no 
significant difference among R1, B1 and B1 dox-treated EBs (Fig 4.9B). 
Taken together, activation of Tbx5 transcription in B1 EBs did not drive the cardiac 
progenitor cells into pacemaker fate.  
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Fig 4.8. The subtype of cardiomyocytes and relative transcripts of R1, B1, B1 Dox-treated 
EBs at Day 21. Fig 4.8A. The percentage of HCN4, Shox2 and Cx43 positive cells were 
analyzed by ICC. Fig 4.8B. MAP3K7/TAK1, Tbx5, Shox2, Tbx3, Tbx18,  HCN4, Nkx2.5, 
Isl1 and Cx43 transcription were assessed by qRT-PCR. Data represent means ± standard 
error of 6 independent experiments, normalized to B1. Statistical significance was 
determined by unpaired, two-tailed t-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Fig 4.9. The subtype of cardiomyocytes and relative transcripts of R1, B1, B1 Dox-treated 
EBs at Day 19. Fig 4.9A. The percentage of HCN4, Shox2 and Cx43 positive cells were 
analyzed by ICC. Fig 4.9B. MAP3K7/TAK1, Tbx5, Shox2, Tbx3, Tbx18,  HCN4, Cx30.2 
and Cx43 transcription were assessed by qRT-PCR. Data represent means ± standard error 
of 3 independent experiments. Statistical significance was determined by unpaired, two-
tailed t-test. *p<0.05, **p<0.01, ***p<0.001. 
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Representative Image of ICC staining 
The golden standard for subtype of cardiomyocytes is to figure out the protein 
expression of cardiac cells: HCN4 and Shox2 for pacemaker marker; Cx43 for ventricular 
marker. Representative images of HCN4 staining of Day 21 (Fig 4.10) and Day 19 (Fig 
4.11) show that HCN4 expressing cells at these time points show morphologies 
charatcteristic of SAN cells. Cardiomyocytes of R1, MAP3K7-Overexpressing, B1, B1 
Dox-treated EBs. At first, GFP positive cardiomyocytes were found under the microscopy 
to confirm its location, and then switch to HCN4 signaling, which expressed in the cell 
cytosol and imaged with DAPI nuclear staining at the same time. Here only GFP and HCN4 
double positive cardiac cells were shown.  
Representative Image of Shox2 staining of Day 21 (Fig 4.12) and Day 19 (Fig 4.13) 
Cardiomyocytes of R1, MAP3K7/TAK1-Overexpressing, B1, B1 Dox-treated EBs. At first, 
GFP positive cardiomyocytes were found under the microscopy to confirm its location, and 
then switch to Shox2 signaling, which expressed in the nuclear sublocation and imaged 
with DAPI nuclear staining at the same time. Here only GFP and Shox2 double positive 
cardiac cells were shown. Surprisingly, in MAP3K7/TAK1-overexpressing EBs at Day 21, 
cardiomyocyte with multiple Shox2 positive nucleus was observed and it was not found in 
other cell type. 
Representative Image of Cx43 staining of Day 21 (Fig 4.14) and Day 19 (Fig 4.15) 
Cardiomyocytes of R1, MAP3K7/TAK1-Overexpressing, B1, B1 Dox-treated EBs. At first, 
GFP positive cardiomyocytes were found under the microscopy to confirm its location, and 
then switch to Cx43 signaling, which expressed in the cell membrane and imaged with 
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DAPI nuclear staining at the same time. Here only GFP and Cx43 double positive cardiac 
cells were shown. At the edge of each cardiomyocyte, Cx43/Gap Junction was lined up as 
dash line to contour the shape of individual cells and most expressed between two cells 
























Fig 4.10. Representative Image of Immnuocytochemistry (ICC) staining of Day 21 
Cardiomyocytes of R1, MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs 
were dissociated into single cell suspension and replated onto chamber slide. Then these 
cells were stained with GFP or DsRed antibody to determine cardiomyocytes based on 
expression of αMHC:GFP or αMHC:mCherry, while HCN4 antibody to figure out the 









Fig 4.11. Representative Image of Immnuocytochemistry (ICC) staining of Day 19 
Cardiomyocytes of R1, MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs 
were dissociated into single cell suspension and replated onto chamber slide. Then these 
cells were stained with GFP or DsRed antibody to determine cardiomyocytes based on 
expression of αMHC:GFP or αMHC:mCherry, while HCN4 antibody to figure out the 







Fig 4.12. Representative Image of ICC staining of Day 21 Cardiomyocytes of R1, 
MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs were dissociated into 
single cell suspension and replated onto chamber slide. Then these cells were stained with 
GFP or DsRed antibody to determine cardiomyocytes based on expression of αMHC:GFP 
or αMHC:mCherry, while Shox2 antibody to figure out the subtype of cardiac cells. Scale 









Fig 4.13. Representative Image of ICC staining of Day 19 Cardiomyocytes of R1, 
MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs were dissociated into 
single cell suspension and replated onto chamber slide. Then these cells were stained with 
GFP or DsRed antibody to determine cardiomyocytes based on expression of αMHC:GFP 
or αMHC:mCherry, while Shox2 antibody to figure out the subtype of cardiac cells. Scale 







Fig 4.14. Representative Image of ICC staining of Day 21 Cardiomyocytes of R1, 
MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs were dissociated into 
single cell suspension and replated onto chamber slide. Then these cells were stained with 
CT3 antibody to determine cardiomyocytes based on expression of αMHC:GFP or 










Fig 4.15. Representative Image of ICC staining of Day 19 Cardiomyocytes of R1, 
MAP3K7/TAK1-overexpressing, B1, B1 Dox-treated EBs. EBs were dissociated into 
single cell suspension and replated onto chamber slide. Then these cells were stained with 
CT3 antibody to determine cardiomyocytes based on expression of αMHC:GFP or 






Here, we produced a mouse embryonic stem cell line B1 (pTripZ-mTbx5; 
αMHC::GFP) that conditionally overexpresses Tbx5. We found that B1 ES cells 
overexpressing Tbx5 showed enhanced overall cardiac differentiation and that cardiac cells 
showed increased beat rates as compared control embryos. Besides, key genes associated 
with SAN differentiation including HCN4 and Shox2 were increased in cells 
overexpressing Tbx5 while other gene associated with early SAN lineage were impacted. 
Despite this, faster beating cells showed a decreased expression of the chamber specific 
marker Cx43 and did not alert in HCN4 or Shox2 positive cardiac cells. These data suggest 
that Tbx5 overexpression is not sufficient for SAN differentiation, although it does activate 









In this chapter, I analyzed the effect of the MAP3K7/TAK1 overexpression on SAN 
differentiation. Using qRT-PCR analyses and FACS data I analyzed gene expression 
comparing wild type EBs to MAP3K7-Overexpressing EBs.  I analyzed both pacemaker 
genes and genes expressed in other lineages relevant to heart induction, specifically 
visceral endoderm (VE), anterior visceral endoderm (AVE) anddefinitive endoderm (DE). 
In addition I examined expression of genes related to Sonic Hedgehog (Shh) signaling.  
 
Cardiomyocytes derived from MAP3K7/TAK1-overexpressing EBs display molecular 
characteristics of the SAN 
To determine if MAP3K7/TAK1-overexpressing EBs influences the cardiac 
differentiation into the SAN fate, qRT-PCR analyses were performed to examine 
pacemaker-specific markers that are already known to direct SAN fate in vivo (reviewed 
in [107]). MAP3K7-overexpressing ES cells were differentiated as EBs and then assessed 
by qRT-PCR for cardiac marker expression from Day 1 to Day 16. During EB 
differentiation, continuous overexpression of MAP3K7 had a profound impact on the 
transcriptional expression of the cardiac progenitor markers like Nkx2.5 and Tbx5 [141]. 
By Day 5, decreased Nkx2.5 transcription in MAP3K7 cells was observed and two days 
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later, by day 7, dramatic increase of Tbx5 transcripts were found in MAP3K7-
overexpressing EBs. 
Within approximately the same differentiation window, mRNAs encoding the 
SAN-specific transcription factors Shox2 and Tbx3 were upregulated, and meanwhile 
cardiac contractile proteins, αMHC, βMHC, were markedly decreased. Other SAN-specific 
markers were either unchanged as compared to wild-type R1 EBs (HCN2) or upregulated 
(HCN4). HCN1, which is not expressed in the SAN of the mouse embryo was expressed 
at similar levels as compared to wild-type R1 EBs, yet the timing of expression was very 
different. 
Isl1 expression was found in cardiac precursors and went down in most 
differentiated myocardial cells. However, Sinus Node cells continued to express Isl1 during 
later differentiation [55]. In MAP3K7-overexpressing cells, three pulses of Isl1 expression 
were observed, while only one of these pulses was observed in wild type R1 cells, the other 
two missing; however, the overall expression pattern was similar between R1 and 
MAP3K7-overexpressing cells. Due to Isl1’s role, non-specific for the sinus node, another 
marker of SAN precursor, Tbx18, was examined.  In addition, we showed that when TAK1 
cells are co-cultured with wild type cells that the wild type cells respond by increasing 
cardiac differentiation, suggesting that TAK1 overexpression leads to the formation of 
cardiogenic tissues.  The lab had also previously shown that gut endoderm markers are 
upregulated in these cells (Hunter, A; Dai, Y. et al, 2019, in revision).  To address this 
possibility I carried out an extensive marker analysis comparing gene expression in the 
TAK1 over-expressing cells to that in wild type cells. 
 73 
Unlike Isl1, Tbx18 (Fig 5.1) was not significantly different between the two 
populations. This data suggests that MAP3K7 acts on established SAN precursors but does 









Fig 5.1. Relative Tbx18 expression during EB differetiation. EBs were collected from Day 
1 to Day 16 and assessed Tbx18 transcription by qRT-PCR between wild-type R1 and 
MAP3K7-overexpressing. Data represent means ± standard error of 3 independent 




MAP3K7/TAK1 specifically upregulates the expression of markers for the cardiogenic 
endoderm. 
Transthyretin, α-feto-protein, Hnf4 and Gata4 are all expressed in both the visceral 
endoderm (VE), which surrounds mouse embryos prior to gastrulation, and in the gut 
endoderm which is made up of both VE and streak-derived definitive endoderm (DE) [144, 
145]. We previously published that TAK1 overexpressing cells also upregulate these 
markers. To clarify if this up regulation of endodermal markers is the result of expansion 
of the VE or DE, or both, specific markers for each of these lineages were assessed.  
First, markers for the AVE were assessed, as this is the source of cardiogenic 
signals in the embryo. Both Cerberus and hHex were significantly upregulated suggesting 
that a MAP3K7 overexpressing EBs do show a general expansion of AVE (Fig 5.2A). 
Interestingly, Dkk1 was not upregulated, suggesting that its expression in the AVE may be 
controlled by another pathway (Fig 5.2A). Sox17, a marker for all early endodermal 
lineages, including the VE and DE was also upregulated but only transiently (Fig 5.2A).  
Markers that are specifically expressed in the DE but not in the VE, including mCXCR4, 
mTM4sf2 and GPC, were not changed in these EBs as compared to wild type controls (Fig 
5.2B). Finally, we assessed the early neural marker Sox2. This was also not significantly 
different than in control EBs (Fig 5.2B). From this we conclude that MAP3K7 dramatically 
and consistently causes an increase in markers for the VE and AVE, but does not affect the 
formation of streak-derived DE. To confirm the role MAP3K7 on endoderm formation, we 
differentiated EBs harboring an endoderm specific promoter reporter, Afp::GFP [146].  
These were treated with the MAP3K7/TAK1 specific inhibitor 5z-7-oxozeaenol.  EBs were 
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treated with the inhibitor from Day 1 to Day 4 of EB differentiation and assessed on Day 
10 for expression of the endoderm reporter (Fig 5.3).  Control EBs grown in the presence 
of the carrier DMSO showed robust endoderm differentiation, as assessed by the presence 
of cells expressing the GFP reporter.  By contrast cells grown in the presence the MAP3K7 
inhibitor showed almost no endoderm formation, even 6 days after the inhibitor was 
removed.  
 
MAP3K7/TAK1 Overexpression leads to up regulation of Shh and Gli2 
It has previously been observed that TGFbeta signaling regulates the expression of 
Sonic Hedgehog (Shh) during gastrulation in Hensen’s node of avian embryos [147]. To 
examine whether SMAD-independent TGFbeta signaling might be involved in regulation 
of Shh, we examined the expression of Shh and several Gli genes by qRT_PCR during EB 
differentiation. Shh and Gli2, but not Gli1 or Gli3 showed robust overexpression in EBs 




Fig 5.2. Quantitative Real-Time PCR data showing transient up regulation of the AVE 
markers Cerberus and hHex, as well as the pan-endodermal marker Sox17 (Fig 5.2A). By 
contrast the AVE Dkk1, which is regulated by Wnt signaling was not upregulated (Fig 
5.2A).  Markers for the definitive endoderm (CXCR4, mTm4sf2 and GPC1) and the early 
neural marker, mSox2 were unaffected in MAP3K7/TAK1 overexpressing EBs (red) as 
compared to control EBs (green line) (Fig 5.2B). Error bars represent standard error of 




Fig 5.3. The effect of MAP3K7/TAK1 inhibitro 5z-7-oxozeaenol during EB differentiation. 
EBs harboring an endoderm specific promoter reporter AFP::GFP were grown in the 
presence of the MAP3K7 inhibitor 5z-7-oxozeaenol from Day 1 to Day 4 of EB 
differentiation showed a significant decrease in endoderm formation as assessed by the 
expression of green fluorescent protein, as compared DMSO-treated controls. (hunter,  A.; 
Dai, Y et al 2019, in revision) 
 
Fig 5.4 Quantitative Real-Time PCR data showing a strong, transient up regulation of Shh 
and Gli2.  Gli1 showed a small but statistically significant up regulation in MAP3K7 
overexpressing EBs (red) as compared to control EBs (green line) and Gli3 was not 
affected. Error bars represent standard error of mean from 3 replicates. Statistical 
significance was determined by unpaired, two-tailed t-test. *p<0.05, **p<0.01. 
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MAP3K7/TAK1 Overexpression does not affect early mesoderm formation 
Given that MAP3K7 seems to specifically expand the VE and AVE in the 
endoderm it was hypothesized that MAP3K7 overexpressing EBs might also show an 
expansion of the cardiac mesoderm. We used qRT-PCR on differentiated EBs to determine 
if MAP3K7 impacted early mesoderm formation by assessing expression of the early 
mesoderm markers T/Brachyury and FGF8. There was a small but statistically significant 
difference between MAP3K7 overexpressing EBs and controls, suggesting that mesoderm 
formation in these cells may be slightly increased.  
We also assessed total cardiac formation on Day 17 in these cells by flow cytometry, 
but found that there was no statistically significant difference between the percentages of 
cardiac cells that formed in the MAP3K7/TAK1-overexpressing EBs as compared to the 








Fig 5.5. Summary of flow cytometry data. Flow cytometry data comparing cardiac 
differentiation in two separate expansions of MAP3K7/TAK1-overexpressing cells (red 
bar) and wild type cells (green bar) based on expression of the cardiac specific promoter 
reporter αMHC::GFP. Error bars in qRT-PCR data indicate standard error from three 
technical replicates. A change in gene expression between MAP3K7-overexpressing and 
wild type EBs is considered relevant if the same change was observed in each of a 
minimum of three biological replicates. Error bars in flow cytometry data represent 





Here, MAP3K7-overexpression EBs did not affect overall cardiac formation. 
Meanwhile, pacemaker marker such as Tbx18, AVE marker (Cerberus, hHex and Dkk1), 
early endoderm marker (Sox17), DE marker (mCXCR4, mTM4sf2 and GPC), early neural 
marker Sox2, Sonic Hedgehog Signaling (Shh and Gli1~3), all these relative transcripts 
were examined during EB differentiation. From all these results, we concluded that 
MAP3K7 dramatically and consistently causes an increase in markers for the VE and AVE, 




SINGLE CELL ANALYSIS OF GENE EXPRESSION DURING MYOCARDIAL 
DIFFERENTIATION  
 
Introduction:   
In this chapter, I will specifically examine the expression of SAN and other cardiac 
markers in cardiomyocytes. In all of these studies we are examining gene expression in 
whole EBs and examining markers that are expressed in the heart and endoderm but are 
also often expressed in other non-cardiac, non-endoderm lineages.  Therefore it is 
sometimes difficult to know whether observed changes are due only changes in the cardiac 
(or endodermal lineage). To address this we have begun to develop a technique that will 
allow us to examine gene expression in just the cardiac lineage.  Briefly, ES cells harboring 
the αMHC::GFP promoter reporter are differentiated until day 21 and cardiomyocytes 
isolated by flow cytometry.  From these cells we isolated RNA and then carried out real 
time PCR for genes expected to be expressed in cardiomyocytes.  A number of technical 
challenges remain to be addressed with this protocol. These data represent promising 




EBs were treated with 0.25% Trypsin/EDTA at 37C for 30 minutes and then 
neutralized with regular differentiation medium. Cells were centrifuged at 2000 rpm for 5 
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minutes and resuspended with FACS buffer. Then cells were centrifuged again and 
resuspended with FACS buffer. Cells were filtered through a 100µm sieve and cell 
numbers were counted using a haemocytometer, checking single cell suspension at the 
same time. Flow cytometry was performed with the Beckman Coulter MoFlo Astrios EQ 
cell sorter and data was analyzed using FlowJo VX software (Fig 5.1). Here is the 
representative analysis of R1 FACS control, R1 and B1 cells. Using two different laser, 
GFP (488-513_26) and PE (488-576_21) laser, we are able to figure out the real GFP 
positive cells based on the gate of R1 FACS Control (0.29%), and will figure out R1 
αMHC::GFP for 1.12% cardiomyocytes and B1 pTripZ-mTbx5; αMHC::GFP for 3.51% 










Fig 6.1. Representative Image of FACS analyze data of R1 FACS Control, R1 αMHC::GFP 




RNA Isolation and Reverse Transcription 
After sorting, 20, 000 (20K) cells from FACS-sorted samples were collected as a 
cell pellet. The RNeasy Plus Micro Kit (Qiagen, cat#74034) was used as manufacturer's 
instructions. The RNA concentration and quality was shown in Table 6.1. The ideal RNA 
A260/A280 is 1.7~2.0. The result of RNA quality was from 0.9~1.37, so the RNA was not 
in good quality.  These data suggest that either the FACS protocol or our RNA isolation 
technique is not sufficient to generate high quality RNA. 
Despite poor 260/280 ratios for isolated RNA we decided to perform reverse 
transcription of RNA samples to synthesis cDNA. Typically we use 800ng-1ug of 
RNA/reaction however because of low RNA yields, we decided to input 10 µl of all 8 
samples regardless of RNA concentration and then adjust the concentrations of the all 8 
cDNAs during the PCR reaction as shown in Table 6.2. Finally, 8.1ng cDNA per PCR 
reaction was added. (We typically add, 40ng of cDNA, for each PCR reaction.) As a result, 
the mean Cross Point (CP) and CP Error calculated automatically from PCR Machine were 









1 R1-2 D19#3 0.9 33.174 10.0 4.4 
2 R1-2 Dox D19#3 1.37 6.574 10.0 4.4 
3 B1 D19#3 1.02 72.39 10.0 4.4 
4 B1 Dox D19#3 1.1 96.71 10.0 4.4 
5 R1-2 D21#3 1.14 12.654 10.0 4.4 
6 R1-2 Dox D21#3 1.13 4.028 10.0 4.4 
7 B1 D21#3 1.01 105.26 10.0 4.4 
8 B1 Dox D21#3 1.35 -3.496 10.0 4.4 
 
Table 6.1. RNA concentration of FACS-sorted samples. 
 





1 R1-2 D19#3 1.65 14.51524 13.4 10.6 8.1 
2 R1-2 Dox D19#3 1.77 11.86512 16.4 7.6 8.1 
3 B1 D19#3 1.72 16.54216 11.7 12.3 8.1 
4 B1 Dox D19#3 1.71 20.1818 9.6 14.4 8.1 
5 R1-2 D21#3 1.75 11.64244 16.7 7.3 8.1 
6 R1-2 Dox D21#3 1.68 16.46996 11.8 12.2 8.1 
7 B1 D21#3 1.76 8.58344 22.6 1.4 8.1 
8 B1 Dox D21#3 1.78 8.09096 24.0 0.0 8.1 
 
Table 6.2. cDNA concentration of FACS-sorted samples. 
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No Name Mean CP CP Error 
1 R1-2 D19#3 26.104 0.112361 
2 R1-2 Dox D19#3 25.454 0.149497 
3 B1 D19#3 23.892 0.017546 
4 B1 Dox D19#3 24.219 0.170053 
5 R1-2 D21#3 23.448 0.305958 
6 R1-2 Dox D21#3 22.026 0.109814 
7 B1 D21#3 22.253 0.436087 
8 B1 Dox D21#3 23.896 0.06666 
 
Table 6.3. Mean CP and CP Error collected from PCR machine.  
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To test the relative transcripts of pacemaker marker like HCN4, Shox2, Tbx3, and 
Isl1, or ventricular marker such as Cx43, qRT-PCR experiments were performed to 
analysis the difference between R1 vs R1 Dox-treated cells , or R1 vs B1 cells , or R1 vs 
B1 Dox-treated cells or B1 vs B1 Dox-treated cells. As shown in Fig 6.2A and Fig 6.2B, 
the batch-to-batch variation between these three trials is so huge. From this, we conclude 
that our input cDNA is outside of the dynamic range of the Roche Lightcycler real time 
PCR machine. Each bar (Fig 6.2A and Fig 6.2B) represented a single independent trial 
from PCR data. At the same time, the range of error bars mean the challenges of artificial 
effect. All different markers were compared, however these was no significant difference 
among all five markers. As discussed, we decided to normalize the expression of each gene 
in a given trial to the value in R1 untreated cardiac cells to get an idea of overall changes 
of gene expression (Fig 6.3A and Fig 6.3B). The relative HCN4 expression of R1 cardiac 
cells is much more than B1 group at Day 19 and R1 had much more Isl1 expression than 
both B1 and B1 Dox-treated group. Meanwhile, at Day 21, B1 Dox-treated cardiac cells 
had more Shox2 and Tbx3 relative expression than R1 untreated group. Taken together, it 




Fig 6.2 HCN4, Shox2, Tbx3, Isl1, Cx43 relative transcription were assessed by qRT-PCR 
for Day 19 cardiac cell (Fig 6.2A) and Day 21 cardiac cell (Fig 6.2B). Data represent means 
± standard error of 3 independent experiments. Statistical significance was determined by 
unpaired, two-tailed t-test.  
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Fig 6.3 HCN4, Shox2, Tbx3, Isl1, Cx43 normalized transcription were assessed by qRT-
PCR for Day 19 cardiac cell (Fig 6.3A) and Day 21 cardiac cell (Fig 6.3B). Data represent 
means ± standard error of 3 independent experiments. Each trial is normalized to R1 




There are still a few challenges from this protocol, especially RNA quality from 
FACS sorted cells. Here are several improvements we will need: 1) Collect 30,000 cardiac 
cells instead of 20,000 cells; 2) Improve RNA Isolation Protocol to generate fairly well 
good RNA quality; 3) Strengthen the capability of PCR protocol to eliminate standard error 






DESIGN AND VERIFICATION OF OVEREXPRESSION LINES 
 
Introduction: 
In this chapter, I will show data verifying gene overexpression in both the Tbx5 and 
other overexpression cell lines. Vincent Christofells has described a transcriptional 
hierarchy that directs the differentiation if sinoatrial node cells in the mouse embryo. The 
major transcription factors involved are: Tbx3, Isl1, Shox2, Tbx18 and MAP3K7/TAK1 
(Fig 7.1) [107, 141].  To study their function in directing SAN differentiation we made ES 
cell lines that will allow us to conditionally overexpress these factors. One of these lines 
(B1, which overexpressed Tbx5) is described in Chapter 4. Detailed information of each 




Fig 7.1. Proposed model of SAN differentiation in MAP3K7/TAK1 Paper.  
No Vector Insert Gene mESCs  
1 pTripZ mTbx3 X1, X6, X13 
2 pTET-ON mTbx3 DX5, DX9 
3 pTripZ hIsl1 I4 
4 pTET-ON hIsl1 DI1, DI2, DI3, DI7 
5 pTripZ hShox2 S2 
6 pTET-ON hShox2 DS13, DS14 
7 pTripZ hTbx18 T2 
8 pTET-ON hTbx18 DT2, DT5 
9 pTripZ MAP3K7 M8 
10 pTET-ON MAP3K7 DM11 
11 pTET-ON mTbx5 DB4, DB6 
 
Table 7.1. List of cell lines discussed in this chapter. 
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Independent clonal lines that conditionally overexpress Tbx3 were established. 
To test the role of Tbx3 in SAN development, mouse embryonic stem cell (mESC) 
lines were generated to conditionally overexpress it by addition of doxycycline. To do this, 
the open reading frame (ORF) of Tbx3 was cloned downstream of the TurboRFP motif 
into the pTripZ vector.  This was used to generate lentivirus and used to transduce wild 
type ES cells. (Fig 7.2A). Another design is to clone Tbx3 ORF into downstream of pTight 
TET-Responsive promoter into the pTET-ON vector (Fig 7.3A), which drives expression 
of the insert GOI with administration of doxycycline. 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation. Genetic studies in mouse have revealed an essential role 
for Tbx3 in establishing the SAN [119, 148]. However, it has not been shown whether 
Tbx3 is sufficient for SAN differentiation. To study its role we established six independent, 
clonal ESC lines (X1, X6, X8, X9, X11, X13), three of these, X1, X6, X13, showed stable 
upregulation of Tbx3 transcripts in an inducible fashion, as assessed by qRT-PCR at 24, 
48 and 72 hours after addition of doxycycline (1 µg /mL) (Fig 7.2B). Other clonal mESC 
lines (DX2, DX3, DX4, DX5, DX6, DX7, DX8 and DX9), two of these,DX5, DX9, 
showed stable upregulation of Tbx3 transcripts as described above (Fig 7.3B). To test the 
best GOI-inducible dose, DX5, DX9 mESCs were treated with doxycycline at 200ng/ml, 
400ng/ml and 800ng/ml and then collected after 48 hours (Fig 7.3C). Later qRT-PCR was 
performed to detect relative expression of Tbx3. DX5 showed upregulation of Tbx3 
expression at dose 400ng/ml, while DX9 showed downregulation of Tbx3 expression at 
dose 400ng/ml. DX5 will be used for future study. 
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A. Addition of Doxycycline increased beat rate in X1 X6 EBs 
One indication that cardiac cells have adopted the SAN identity, is an increase rate 
of beating speed. To determine if any of our mESCs could differentiate towards SAN cells 
in response to increased expression of Tbx3. mESCs were differentiated as EBs and 
doxycycline added from Day 2 to Day 16 at which point beat rate data was collected and 
assessed. X1, X6 EBs were tested for increased beat rate with working dose curve of 
doxycycline (Fig 7.2C). Beating areas were identified based on visual inspection and 
confirmed by expression of αMHC::GFP. Beat was manually calculated but visual 
inspection counting beats/minute. Lines X1 showed a modest increase in beat rate at 200 
ng/ml.  Line X6 showed significant increase in beat rate at 100ng/ml, 200ng/ml and 
500ng/ml. For this reason, line X1 and X6 were used for all subsequent evaluation. 
B. Relative Tbx3 RNA Expression during EB differentiation 
Although addition of Dox worked well in X1 and X6 mESCs, regulation of gene 
expression within differentiating EBs is much more complicated. To test whether addition 
of Dox also upregulated Tbx3 transcripts during EB differentiation, EBs were collected 
from Day 1 to Day 11 and assessed Tbx3 transcription by qRT-PCR (Fig 7.4).  
Interestingly, X1 EBs showed a modest increase of Tbx3 transcripts without 
doxycycline compared to parent R1 cell line, while X6 EBs showed the similar level of 
Tbx3 expression. X1 Dox-treated EBs only showed increased Tbx3 expression at Day 3 
and the same for Day 5 to D11 compared to X1 untreated EBs, while X6 Dox-treated EBs 
showed increased Tbx3 expression at Day 5, Day 7 and Day 9. For this reason, line X6 was 
used for future analysis.  
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Fig 7.2. Verification of X1, X6 pTripZ-mTbx3; αMHC::GFP mouse embryonic stem cell 
line. Fig 7.2A. Schematic design of pTripZ-mTbx3 Vector, doxycycline-inducible-Tbx3-
overexpression backbone. Fig 7.2B. X1, X6, X8, X9, X11, X13 mESCs were treated with 
doxycycline at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Tbx3. Fig 7.2C. Manual beat data counting of 
X1, X6 EBs at Day 16 with Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 100ng/ml, 
200ng/ml and 500ng/ml. Data represent means ± standard error of 3 independent 




Fig 7.3. Verification of DX5, DX9 pTET-ON-mTbx3; αMHC::GFP mouse embryonic 
stem cell line. Fig 7.3A. Schematic design of pTET-ON-mTbx3 Vector, doxycycline-
inducible-Tbx3-overexpression backbone. Fig 7.3B. DX2, DX3, DX4, DX5, DX6, DX7, 
DX8 and DX9 mESCs were treated with doxycycline at 1 µg /mL and then collected after 
0, 24, 48, 72h. Later qRT-PCR was performed to detect relative expression of Tbx3. Fig 
7.3C. DX5, DX9 mESCs were treated with doxycycline at 0ng/ml, 200ng/ml, 400ng/ml 
and 800ng/ml and then collected after 48 hours. Later qRT-PCR was performed to detect 
relative expression of Tbx3. Data represent means ± standard error of 3 independent 




Fig 7.4. Relative Tbx3 expression during EB differetiation. EBs were collected from Day 
1 to Day 11 and assessed Tbx3 transcription by qRT-PCR among X1 Dox-treated or 
untreated EBs and R1 EBs (Fig 7.4A) and among X6 Dox-treated or untreated EBs and R1 




Independent clonal line that conditionally overexpress hIsl1 was established. 
To test the role of Isl1 in SAN development, mESC lines were generated to 
conditionally overexpress hIsl1. To do this, the open reading frame of hIsl1 was cloned 
downstream of the TurboRFP motif into the pTripZ vector. This was used to generate 
lentivirus in which GOI can be overexpressed by the administration of Doxycycline (Fig 
7.5A). Another design is to clone Isl1 ORF into downstream of pTight TET-Responsive 
promoter into the pTET-ON vector (Fig 7.6A), which drives expression of the insert GOI 
with administration of Doxycycline. 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation. Downstream of this cascade is Isl1. Genetic studies in 
mouse have revealed an essential role for Isl1 in establishing the SAN [149, 150]. However, 
it has not been shown whether Isl1 is sufficient for SAN differentiation. To study its role 
we established five independent, clonal ESC lines (I2, I3, I4, I5, I6), only I4 showed stable 
upregulation of Isl1 transcripts in an inducible fashion, as assessed by qRT-PCR at 24, 48 
and 72 hours after addition of doxycycline (1 µg /mL) (Fig 7.5B). Other clonal mESC lines 
(DI1, DI2, DI3, DI4, DI6 and DI7), two of all DI1, DI3 showed stable upregulation of Isl1 
transcripts as described above (Fig 7.6B). To test the best GOI-inducible dose, DI1, DI3 
mESCs were treated with doxycycline at 0ng/ml, 50ng/ml, 100ng/ml and 200ng/ml and 
then collected after 48 hours (Fig 7.6C). Later qRT-PCR was performed to detect relative 
expression of Isl1. Both DI1 and DI3 did not show upregulation of Isl1. Other potential 
cell lines (DI2 and DI7) will be tested in the future study.   
A. Addition of Doxycycline increased beat rate in I4 EBs 
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One indication that cardiac cells have adopted the SAN identity, is an increase rate 
of beating speed. To determine if any of our mESCs could differentiate towards SAN cells 
in response to increased expression of Isl1. mESCs were differentiated as EBs and 
doxycycline added from Day 2 to Day 16 at which point beat rate data was collected and 
assessed. I4 EBs were tested for increased beat rate with working dose curve of 
doxycycline (Fig 7.5C). Beating areas were identified based on visual inspection and 
confirmed by expression of αMHC::GFP. Beat was manually calculated but visual 
inspection counting beats/minute. Lines I4 showed a modest increase in beat rate at 500 
ng/ml. For this reason, line I4 was used for all subsequent evaluation. 
B. Relative Isl1, Tbx5, Tbx3, Nkx2.5 RNA Expression during EB differentiation 
Although addition of Dox worked well in I4 mESCs, regulation of gene expression 
within differentiating EBs is much more complicated. To test whether addition of Dox also 
upregulated Isl1 transcripts during EB differentiation, EBs were collected from Day 1 to 
Day 16 and assessed Isl1, Tbx5, Tbx3, Nkx2.5 transcription by qRT-PCR (Fig 7.7). 
Interestingly, I4 Dox-treated EBs showed increase Isl1 expression at Day 2, Day 5, Day 6 
and Day 8 compared to I4 untreated EBs. Then I4 Dox-treated EBs showed four pulses of 
Tbx5 upregulation at Day 6, 8, 10 and 13; one pulse of Tbx3 upregulation at Day 6; two 
pulses of Nkx2.5 upregulation at Day 8 and 13. For this experiment only one trial is 






Fig 7.5. Verification of I4 pTripZ-hIsl1; αMHC::GFP mouse embryonic stem cell line. Fig 
7.5A. Schematic design of pTripZ-hIsl1 Vector, doxycycline-inducible-Isl1-
overexpression backbone. Fig 7.5B. I2, I3, I4, I5 and I6 mESCs were treated with 
doxycycline at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Isl1. Fig 7.5C. Manual beat data counting of I4 
EBs at Day 15 with Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 100ng/ml, 200ng/ml 
and 500ng/ml. Data represent means ± standard error of 3 independent experiments. 
Statistical significance was determined by one-way ANOVA. **p<0.01. 
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Fig 7.6. Verification of DI1, DI3 pTET-ON-hIs1; αMHC::GFP mouse embryonic stem cell 
line. Fig 7.6A. Schematic design of pTET-ON- hIs1 Vector, doxycycline-inducible-Is1-
overexpression backbone. Fig 7.6B. DI1, DI2, DI3, DI4, DI6 and DI7 mESCs were treated 
with doxycycline at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Is1. Fig 7.6C. DI1, DI3 mESCs were treated 
with doxycycline at 0ng/ml, 50ng/ml, 100ng/ml and 200ng/ml and then collected after 48 
hours. Later qRT-PCR was performed to detect relative expression of Is1. Data represent 
means ± standard error of 3 independent experiments. Statistical significance was 







Fig 7.7. Relative Isl1, Tbx5, Tbx3, Nkx2.5 expression during EB differetiation. EBs were 
collected from Day 1 to Day 16 and assessed Tbx3 transcription by qRT-PCR between I4 
Dox-treated or I4 untreated EBs (Fig 7.7). Data represent means ± standard error of one 




Independent clonal line that conditionally overexpress hShox2 was established. 
To test the role of Shox2 in SAN development, mESC lines were generated to 
conditionally overexpress hShox2. To do this, the open reading frame of hShox2 was 
cloned downstream of the TurboRFP motif into the pTripZ vector. This was used to 
generate lentivirus in which GOI can be overexpressed by the administration of 
Doxycycline (Fig 7.8A). Another design is to clone Shox2 ORF into downstream of pTight 
TET-Responnsive promoter into the pTET-ON vector (Fig 7.9A), which drives expression 
of the insert GOI with administration of Doxycycline. 
 Genetic studies in mouse have revealed an essential role for Shox2 in establishing 
the SAN [113, 151, 152]. However, it has not been shown whether Shox2 is sufficient for 
SAN differentiation.  To study its role we established six independent, clonal ESC lines 
(S1, S2, S7, S10, S14 and S16), only S2 showed stable upregulation of Shox2 transcripts 
in an inducible fashion, as assessed by qRT-PCR at 24, 48 and 72 hours after addition of 
doxycycline (1 µg /mL) (Fig 7.8B). Other clonal mESC lines (DS13, DS14), both showed 
stable upregulation of Shox2 transcripts as described above (Fig 7.9B). To test the best 
GOI-inducible dose, DS13 and DS14 mESCs were treated with doxycycline at 0ng/ml, 
50ng/ml, 100ng/ml and 200ng/ml and then collected after 48 hours (Fig 7.9C). Later qRT-
PCR was performed to detect relative expression of Shox2. DS13 showed downregulation 
of Shox2 at dose 200ng/ml, while DS14 showed upregulation of Shox2 at dose 50ng/ml. 
DS14 will be used in the future study.   
A. Addition of Doxycycline did not increase beat rate in S2 EBs 
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One indication that cardiac cells have adopted the SAN identity is an increase rate 
of beating speed. To determine if any of our mESCs could differentiate towards SAN cells 
in response to increased expression of Shox2. mESCs were differentiated as EBs and 
doxycycline added from Day 2 to Day 16 at which point beat rate data was collected and 
assessed. S2 EBs were tested for increased beat rate with working dose curve of 
doxycycline (Fig 7.8C). Beating areas were identified based on visual inspection and 
confirmed by expression of αMHC::GFP. Beat was manually calculated but visual 
inspection counting beats/minute.  Line S2 with administration of Dox did not increase 





Fig 7.8. Verification of S2 pTripZ-hShox2; αMHC::GFP mouse embryonic stem cell line. 
Fig 7.8A. Schematic design of pTripZ-hShox2 Vector, doxycycline-inducible-Shox2-
overexpression backbone. Fig 7.8B. S1, S2, S7, S10, S14 and S16 mESCs were treated 
with doxycycline at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Isl1. Fig 7.8C. Manual beat data counting of S2 
EBs at Day 15 or Day 16 with Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 100ng/ml, 
200ng/ml and 500ng/ml. Data represent means ± standard error of 3 independent 
experiments. Statistical significance was determined by one-way ANOVA. 
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Fig 7.9. Verification of DS13, DS14 pTET-ON-hShox2; αMHC::GFP mouse embryonic 
stem cell line. Fig 7.9A. Schematic design of pTET-ON-hShox2 Vector, doxycycline-
inducible-Shox2-overexpression backbone. Fig 7.9B. DS13 and DS14 mESCs were treated 
with doxycycline at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was 
performed to detect relative expression of Is1. Fig 7.9C. DS13 and DS14 mESCs were 
treated with doxycycline at 0ng/ml, 50ng/ml, 100ng/ml and 200ng/ml and then collected 
after 48 hours. Later qRT-PCR was performed to detect relative expression of Shox2. Data 
represent means ± standard error of 3 independent experiments. Statistical significance was 
determined by unpaired, two-tailed t-test. **p<0.01, ***p<0.001. 
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Independent clonal line that conditionally overexpress hTbx18 was established. 
To test the role of Tbx18 in SAN development, mESC lines were generated to 
conditionally overexpress hTbx18. To do this, the open reading frame of hTbx18 was 
cloned downstream of the TurboRFP motif into the pTripZ vector.  This was used to 
generate lentivirus in which GOI can be overexpressed by the administration of 
Doxycycline (Fig 7.10A). Another design is to clone Tbx18 ORF into downstream of 
pTight TET-Responsive promoter into the pTET-ON vector (Fig 7.11A), which drives 
expression of the insert GOI with administration of Doxycycline. 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation. Downstream of Tbx5 is Tbx18. Genetic studies in mouse 
have revealed an essential role for Tbx18 in establishing the SAN [84, 153-155]. However, 
it has not been shown whether Tbx18 is sufficient for SAN differentiation.  To study its 
role in SAN differentiation, we established one independent, clonal ESC lines (T2), which 
showed stable upregulation of Tbx18 transcripts in an inducible fashion, as assessed by 
qRT-PCR at 24, 48 and 72 hours after addition of doxycycline (1 µg /mL) (Fig 7.10B). 
Other clonal mESC lines (DT2, DT4, DT5, DT7, DT8, DT9 and DT10), DT2 and DT5 
showed stable upregulation of Shox2 transcripts as described above (Fig 7.11B). To test 
the best GOI-inducible dose, DT2 and DT5 mESCs were treated with doxycycline at 
0ng/ml, 200ng/ml, 400ng/ml and 800ng/ml and then collected after 48 hours (Fig 7.11C). 
Later qRT-PCR was performed to detect relative expression of Tbx18. Both DT2 and DT5 
did not show upregulation of Tbx18. Other potential cell lines (DT8, DT9 and DT10) will 
be tested in the future study.   
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A. Addition of Doxycycline did increase beat rate in T2 EBs 
One indication that cardiac cells have adopted the SAN identity, is an increase rate 
of beating speed. To determine if any of our mESCs could differentiate towards SAN cells 
in response to increased expression of Tbx18. mESCs were differentiated as EBs and 
doxycycline added from Day 2 to Day 16 at which point beat rate data was collected and 
assessed. T2 EBs were tested for increased beat rate with working dose curve of 
doxycycline (Fig 7.10C).  Beating areas were identified based on visual inspection and 
confirmed by expression of αMHC::GFP.  Beat was manually calculated but visual 
inspection counting beats/minute.  Line T2 showed significant increase at 200ng/ml at Day 






Fig 7.10. Verification of T2 pTripZ-hTbx18; αMHC::GFP mouse embryonic stem cell line. 
Fig 7.10A. Schematic design of pTripZ-hTbx18 Vector, doxycycline-inducible-Tbx18-
overexpression backbone. Fig 7.10B. T2 mESCs were treated with doxycycline at 1 µg 
/mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was performed to detect 
relative expression of Isl1. Fig 7.10C. Manual beat data counting of T2 EBs at Day 15 with 
Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 100ng/ml, 200ng/ml and 500ng/ml. 
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Fig 7.11. Verification of DT2, DT5 pTET-ON-hTbx18; αMHC::GFP mouse embryonic 
stem cell line. Fig 7.11A. Schematic design of pTET-ON-hTbx18 Vector, doxycycline-
inducible-Tbx18-overexpression backbone. Fig 7.11B. DT2, DT4, DT5, DT7, DT8, DT9 
and DT10 mESCs were treated with doxycycline at 1 µg /mL and then collected after 0, 
24, 48, 72h. Later qRT-PCR was performed to detect relative expression of Tbx18. Fig 
7.11C. DT2 and DT5 mESCs were treated with doxycycline at 0ng/ml, 200ng/ml, 
400ng/ml and 800ng/ml and then collected after 48 hours. Later qRT-PCR was performed 
to detect relative expression of Tbx18. Data represent means ± standard error of 3 
independent experiments. Statistical significance was determined by unpaired, two-tailed 
t-test.  
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Independent clonal lines that conditionally overexpress MAP3K7/TAK1 were 
established. 
To test the role of MAP3K7/TAK1 in SAN development, mESC lines were 
generated to conditionally overexpress MAP3K7. To do this, the open reading frame of 
MAP3K7 was cloned downstream of the TurboRFP motif into the pTripZ vector. This was 
used to generate lentivirus in which GOI can be overexpressed by the administration of 
Doxycycline (Fig 7.12A). Another design is to clone MAP3K7 ORF into downstream of 
pTight TET-Responnsive promoter into the pTET-ON vector (Fig 7.13A), which drives 
expression of the insert GOI with administration of Doxycycline. 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation. Upstream of Tbx5 is MAP3K7. Genetic studies in mouse 
have revealed an essential role for MAP3K7 in establishing the SAN [141, 156]. 
Continuous expression of MAP3K7 directed ES-derived cardiomyocytes into pacemaker 
fate. However, it has not been shown whether conditional expression of MAP3K7 is 
sufficient for SAN differentiation.  To study its role we established four independent, clonal 
ESC lines (M8, M10, M11, M14), only M8 which showed stable upregulation of MAP3K7 
transcripts in an inducible fashion, as assessed by qRT-PCR at 24, 48 and 72 hours after 
addition of doxycycline (1 µg /mL) (Fig 7.12B). Other clonal mESC lines (DM1, DM2, 
DM3, DM5, DM8, DM9, DM10, DM11, DM12 and DM13), DM11 showed stable 
upregulation of MAP3K7 transcripts as described above (Fig 7.13B). M8 will be used in 
the subsequent experiments.  
A. Addition of Doxycycline did increase beat rate in M8 EBs 
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One indication that cardiac cells have adopted the SAN identity is an increase rate 
of beating speed. To determine if any of our mESCs could differentiate towards SAN cells 
in response to increased expression of MAP3K7. mESCs were differentiated as EBs and 
doxycycline added from Day 2 to Day 16 at which point beat rate data was collected and 
assessed. M8 EBs were tested for increased beat rate with working dose curve of 
doxycycline (Fig 7.12C).  Beating areas were identified based on visual inspection and 
confirmed by expression of αMHC::GFP. Beat was manually calculated but visual 
inspection counting beats/minute.  Line M8 showed significant increase at both 100ng/ml 
and 200ng/ml at Day 16. Line M8 will be used for future study. 
B. Relative MAP3K7 Expression during EB differentiation 
Although addition of Dox worked well in M8 or DM11 mESCs, yet regulation of 
gene expression within differentiating EBs is much more complicated.  To test whether 
addition of Dox also upregulated MAP3K7 transcripts during EB differentiation, EBs were 
treated with Dox dose of 0ng/ml, 200ng/ml, 500ng/ml, 1000ng/ml and 2000ng/ml from 
Day 4 to Day 7 (Fig 7.12D&Fig 7.13C). Then EBs were collected at Day 7 and relative 
MAP3K7 expression was assessed by qRT-PCR. Surprisingly, only M8 EBs treated with 
Dox dose of 200ng/ml, which was consistent with the dose tested for fast beating 
cardiomyocytes. Line M8 associated with Dox Dose 200ng/ml will be used for future study. 
Meanwhile, DM11 EBs treated with 500ng/ml or 2000ng/ml showed significant increase 
of MAP3K7 transcripts compared to untreated controls. Line DM11 and dose 500ng/ml 
will be used in the future study.  
C. MAP3K7 overexpression did not increase overall cardiac formation 
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Our data has shown that MAP3K7-overexpressing EBs did not increase overall 
cardiac differentiation at Day in chapter four. Our next step is to figure out conditional 
expression of MAP3K7 effect on cardiac formation. To test this, EBs were differentiated 
with or without the addition of Dox from Day 4 to Day 19 (Fig 7.13D). Cells were isolated 
at Day 15 and Day 19. The percentage of cardiac differentiation was assessed based on 
expression of GFP by flow cytometry. DM11 Dox-treated EBs had no significant increase 




Fig 7.12. Verification of M8 pTripZ-MAP3K7; αMHC::GFP mouse embryonic stem cell 
line. Fig 7.12A. Schematic design of pTripZ- MAP3K7 Vector, doxycycline-inducible- 
MAP3K7-overexpression backbone. Fig 7.12B. M8 mESCs were treated with doxycycline 
at 1 µg /mL and then collected after 0, 24, 48, 72h. Later qRT-PCR was performed to detect 
relative expression of Isl1. Fig 7.12C. Manual beat data counting of M8 EBs at Day 16 
with Doxycycline dose of 0ng/ml, 20ng/ml, 40ng/ml, 100ng/ml, 200ng/ml and 500ng/ml. 
Fig 7.12D. M8 EBs were treated with Dox dose of 0ng/ml, 200ng/ml, 500ng/ml, 1000ng/ml 
and 2000ng/ml from Day 4 to Day 7. Then EBs were collected at Day 7 and relative 
MAP3K7 expression was assessed by qRT-PCR. Data represent means ± standard error of 




Fig 7.13. Verification of DM11 pTET-ON-MAP3K7; αMHC::GFP mouse embryonic stem 
cell line. Fig 7.13A. Schematic design of pTET-ON-MAP3K7 Vector, doxycycline-
inducible-MAP3K7-overexpression backbone. Fig 7.13B. DM1, DM2, DM3, DM5, DM8, 
DM9, DM10, DM11, DM12 and DM13 mESCs were treated with doxycycline at 1 µg /mL 
and then collected after 0, 24, 48, 72h. Later qRT-PCR was performed to detect relative 
expression of MAP3K7. Fig 7.13C. M8 EBs were treated with Dox dose of 0ng/ml, 
200ng/ml, 500ng/ml, 1000ng/ml and 2000ng/ml from Day 4 to Day 7. Then EBs were 
collected at Day 7 and relative MAP3K7 expression was assessed by qRT-PCR. Fig 7.13 
D. EBs were differentiated with or without the addition of Doxycycline from Day 4 to Day 
19 and analyzed at Day 15 and Day 19. The percentage of cardiomyocytes was determined 
by Flow Cytometry Data represent means ± standard error of 3 independent experiments. 




Independent clonal lines that conditionally overexpress Tbx5 were established. 
To test the role of Tbx5 in SAN development, mESC lines were generated to 
conditionally overexpress Tbx5. Besides B1, new design is to clone Tbx5 ORF into 
downstream of pTight TET-Responnsive promoter into the pTET-ON vector (Fig 7.14A), 
which drives expression of the insert GOI with administration of Doxycycline. 
These vectors can be used to conditionally overexpress all of the key transcriptional 
regulators of SAN differentiation. At the top of this cascade is Tbx5. Genetic studies in 
mouse have revealed an essential role for Tbx5 in establishing the SAN. However, it has 
not been shown whether conditional expression of Tbx5 is sufficient for SAN 
differentiation. To study its role we established four independent, clonal ESC lines (DB3, 
DB4, DB6, DB7, DB8 and DB10), DB4 and DB6 which showed stable upregulation of 
Tbx5 transcripts in an inducible fashion, as assessed by qRT-PCR at 24, 48 and 72 hours 
after addition of doxycycline (1 µg /mL) (Fig 7.14B). To test the best GOI-inducible dose, 
DB4 and DB6 mESCs were treated with doxycycline at 0ng/ml, 50ng/ml, 100ng/ml and 
200ng/ml and then collected after 48 hours (Fig 7.14C). Later qRT-PCR was performed to 
detect relative expression of Tbx5. Surprisingly, both DB4 and DB6 treated with 100 and 
200ng/ml dose of Dox showed upregulation of Tbx5.  
A. Relative Tbx5 Expression during EB differentiation 
Although addition of Dox worked well in DB4 and DB6 mESCs, yet regulation of 
gene expression within differentiating EBs is much more complicated.  To test whether 
addition of Dox also upregulated Tbx5 transcripts during EB differentiation, EBs were 
treated with Dox dose of 0ng/ml, 200ng/ml, 500ng/ml, 1000ng/ml and 2000ng/ml from 
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Day 4 to Day 7 (Fig 7.14D). Then EBs were collected at Day 7 and relative Tbx5 
expression was assessed by qRT-PCR. Surprisingly, DB4 EBs showed upregulation of 
Tbx5 with dose 500ng/ml and 1000ng/ml, while DB6 showed significant increase of Tbx5 
with dose 1000ng/ml and 2000ng/ml. As a result, DB4 with dose 500ng/ml and DB6 with 
dose 1000ng/ml will be used in the subsequent experiments.  
B. Tbx5 overexpression may increase overall cardiac formation 
Tbx5 is a key player in cardiac development. Since DB4 and DB6 naturally 
expresses higher levels of Tbx5 at Day 7 (Fig 7.15A), it might be more active in 
cardiogenesis. To test this, EBs were differentiated with or without the addition of dox 
from Day 4 to Day 17 (Fig 7.15B) and from Day 4 to Day 19 (Fig 7.15C). Cells were 
isolated at Days 15, 17 and 19. The percentage of cardiac differentiation was assessed based 
on expression of GFP by flow cytometry. Interestingly, at Day 17, both DB4 and DB6 had 
no significant increase compared to R1, while at Day 15 and Day 19, DB6 untreated EBs 
had more cardiac cells. DB6 Dox-treated EBs had no significant change.  
C. Subtype of Differentiated Cardiomyocytes  
Immunocytochemistry (ICC) staining is current standard to figure out cardiac 
subtype based on protein expression, such as HCN4 and Shox2 for pacemaker marker or 
Cx43 for ventricular marker. Here four different EBs including R1, MAP3K7/TAK1-
overexpressing EBs (pgk:MAP3K7/TAK1; αMHC:mCherry) [141], B1 untreated, B1 
Dox-treated were analyzed for HCN4, Shox2 and Cx43 positive cardiomyocytes (Fig 
7.16A). MAP3K7/TAK1-overexpressing EBs had more HCH4 and Shox2 positive 
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cardiomyocytes than R1 EBs, however there was no significant difference either between 
R1 and DB6, or between DB6 and DB6 dox-treated EBs. 
At the same time, whole EBs from R1, DB6 and DB6 Dox-treated group were 
collected and later assessed by qRT-PCR at Day 17 (Fig 7.16B). DB6 EBs had significant 
higher levels of MAP3K7 transcripts than the parent cell line R1, while DB6 Dox-treated 






Fig 7.14. Verification of DB4, DB6 pTET-ON-mTbx5; αMHC::GFP mouse embryonic 
stem cell line. Fig 7.14A. Schematic design of pTET-ON-mTbx5 Vector, doxycycline-
inducible-Tbx5-overexpression backbone. Fig 7.14B. DB3, DB4, DB6, DB7, DB8 and 
DB10 mESCs were treated with doxycycline at 1 µg /mL and then collected after 0, 24, 48, 
72h. Later qRT-PCR was performed to detect relative expression of Tbx5. Fig 7.14C. DB4 
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and DB6 mESCs were treated with doxycycline at 0ng/ml, 50ng/ml, 100ng/ml and 
200ng/ml and then collected after 48 hours. Later qRT-PCR was performed to detect 
relative expression of Tbx5. Fig 7.14D. DB4 and DB6 EBs were treated with Dox dose of 
0ng/ml, 200ng/ml, 500ng/ml, 1000ng/ml and 2000ng/ml from Day 4 to Day 7. Then EBs 
were collected at Day 7 and relative Tbx5 expression was assessed by qRT-PCR. Data 
represent means ± standard error of 3 independent experiments. Statistical significance was 
determined by unpaired, two-tailed t-test. *p<0.05, **p<0.01, ****p<0.0001. 
 
Fig 7.15. Cardiac differentiation analyzed by Flow Cytometry. EBs were collected at Day 
7 and assess by qRT-PCR (Fig 7.15A). Fig 7.15B&C. EBs were differentiated with or 
without the addition of Doxycycline from Day 4 to Day 17 (Fig 7.15B) and from Day 4 to 
Day 19 (Fig 7.15C). The percentage of cardiomyocytes was determined by Flow 
Cytometry Data represent means ± standard error of 3 independent experiments. Statistical 




Fig 7.16. The subtype of cardiomyocytes of R1, DB6, DB6 Dox-treated EBs at Day 19 and 
relative transcripts at Day 17. The percentage of HCN4 and Shox2 positive cardiomyoctes 
among all cardiomyocytes were analyzed by Immmunocytochemistry and shown in Fig 
7.16A, Tbx5, HCN4, Shox2, MAP3K7 and Cx43 transcription were assessed by qRT-PCR 
and shown in Fig 7.16B. Data represent means ± standard error of 3 independent 




Here, I list all mESCs that I produce and all characteristics of each individual cell 
line (Table 7.2). For gene Tbx3, pTripZ-mTbx3 X6 and dose of 200ng/ml is the best choice; 
for gene Isl1, pTripZ-hIsl1 I4 and dose of 500ng/ml is the first choice; for gene, Shox2, 
pTET-ON-hShox2 DS14 and dose of 50ng/ml is the first choice; for gene Tbx18, pTripZ-
hTbx18 T2 and dose of 100ng/ml is the best choice; for gene MAP3K7, pTripZ-MAP3K7 
M8 and dose of 200ng/ml is the best choice; for gene Tbx5, pTET-ON-mTbx5 DB6 and 
dose of 1000ng/ml is the first choice. Taken together, we can study these pacemaker-
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A transcriptional cascade that mediates SAN differentiation. 
Vincent Christofells elucidated the transcriptional program involved in SAN 
differentiation from mesodermal precursors in the mouse (Fig 8.1). With the help of 
transgenic mice and the advancement of lineage tracing techniques, the progenitors of the 
SAN cells and the transcriptional program directing their differentiation have been well-
established [117]. Mommersteeg and colleagues demonstrated that around E8, the sinus 
venosus develops from Tbx18+/Nkx2.5-/Isl1- progenitors, apart from the rest of the cardiac 
mesoderm. At E8.5, some of these cells begin to express Islet1, and later at E9.5, a subset 
within the sinus venosus starts to express Tbx3, a transcription factor (TF) that represses 
chamber development [118]. Tbx3 is continuously expressed during cardiac development 
in the forming mature conduction system, comprising both the SAN and the bundle 
branches of the ventricular conduction system. Shox2, like Tbx18, has an expression 
pattern complementary to that of Nkx2.5, the TF that activates cardiac chamber formation 
[113]; Shox2 is a repressor of the Nkx2.5 gene, thus preventing chamber myocardium 
formation in the SAN, while allowing SAN-specific gene expression, such as Tbx3 and 
HCN4 [114]. These data suggest that pacemaker cells derive from the activation of a 
particular genetic pathway in progenitors during cardiogenesis of the SAN. 
The Foley lab recently reported that overexpression of MAP3K7/TAK1 in mESC-
derived cardiomyocytes faithfully directed cardiac progenitor cells into the SAN lineage. 
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Most cardiac cells in MAP3K7/TAK1-overexpressing EBs adopted pacemaker markers, 
cellular morphologies and electrophysiological behaviors characteristics of the SAN fate. 
MAP3K7/TAK1 proved, by qRT-PCR analysis, to be an upstream regulator of pacemaker 















ES cell lines with overexpression of Tbx3, Isl1, Shox2 and Tbx18 
In 2013, the Cho lab genetically transduced the TF, Tbx18, into neonatal rat 
ventricular myocytes (NRVMs), which converted NRVMs into SAN pacemaker-like (SAN) 
cells [84]. In vivo, gene transfer of Tbx18 in the guinea pig heart yielded ectopic pacemaker 
activity, restoring a bradycardic phenotype [84]. One year later, the David lab showed that 
pure populations of physiologically and pharmacologically functional pacemaker cells 
could be obtained by overexpressing the SAN-inducing TF, Tbx3, in mouse embryonic 
stem cells (mESCs); these were differentiated as embryoid bodies (EBs), and 
cardiomyocytes were purified based on an Myh6 promoter-based antibiotic selection [157]. 
In 2015, the Cho lab demonstrated that TF, Shox2, overexpression during EB 
differentiation of mESCs resulted in upregulation of the pacemaker genetic program [151]. 
Similarly, the TF, Isl1 overexpression in mESCs was shown to promote differentiation of 
cardiomyocytes with electrophysiological profiles typical of pacemaker cells [149]. Taken 
together, these data suggest that TFs can activate (or select for) the differentiation of SAN 
cells from ESCs. However, these studies do not completely address all criteria for SAN 
cell differentiation and, in most cases, the efficiency of SAN conversion was low [151, 
157]. Additionally, purported pacemaker cells in some cases expressed the ventricular 
inward rectifier Ik1 [151] suggesting that these had hybrid ventricular/SAN characteristics.  
Also some of these cells did not express physiologically normal levels or the pacemaker-
specific inward funny (If) current suggesting that they were immature SAN-like cells [157]. 
Biological pacing in this model peaked around day 7 and waned by day 14 due to the 
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declining heart rate [84], showing that biological pacing was not successfully maintained 
in the absence of these transgenes.  
These suggest that TFs downstream of Tbx5 were not sufficient for permanent 
conversion of ES cells to the pacemaker fate. To determine whether Tbx5 could activate 
pacemaker fates I made a cell line to conditionally overexpress Tbx5 (B1). 
 
Data Interpretation from Tbx5-Overexpressing B1 EBs 
From beat data at D19 and D21, we observed something different in B1 and B1 
Dox-treated EBs (Fig 8.3A). At the same time, we checked the relative Tbx5 transcripts at 
D19 and D21 (Fig 8.3B). Interesting, B1 Dox-treated EBs had more Tbx5 transcripts at 
D19 and less Tbx5 transcripts at Day 21, compared to B1 untreated EBs, meanwhile, B1 
treated EBs had faster beating cells than B1 untreated EBs only at Day 21, not at Day 19. 
These data suggested that the loss of Tbx5 in B1 Dox-treated EBs might be the reason for 
fast beating cardiomyocytes.  Tbx5 may be lost in adult mature cardiomyocytes.  
Next, to figure out the expression of all downstream marker of Tbx5, such as Shox2, 
Isl1, Tbx3, Tbx18, HCN4 and also ventricular marker Nkx2.5 and Cx43 (Fig 8.4). 
Compared to R1 wild type, the Tbx5 overexpressing cell line B1 had a pattern that activated 
downstream Shox2, Isl1, Tbx3, Tbx18, HCN4, but did not inhibit Nkx2.5 and Cx43 
transcripts. Upstream MAP3K7/TAK1 did not change among R1, B1, B1 Dox-treated EBs. 
In order to figure out the subtype of cardiomyocytes of R1, MAP3K7/TAK1-
overexpressiong, B1, B1 Dox-treated EBs, ICC staining was performed on these four 
groups (Fig 8.5). To our surprise, either B1 Dox-treated EBs or B1 untreated EBs did not 
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adopt HCN4 or Shox2 pacemaker phenotype even with increased HCN4 and Shox2 
transcripts. In other words, cardiac cells derived from B1 or B1 Dox-treated EBs did not 
express transcription factors associated with the SAN fate. Meanwhile, B1 and B1 Dox-
treated EBs had less Cx43 positive population compared to R1 ventricle phenotype, more 
Cx43 cardiac cells compared to MAP3K7/TAK1 pacemaker phenotype. Surprisingly, 
compare to B1 untreated EBs, B1 Dox-treated EBs had less Cx43 positive myocytes, which 
explained why fast beating myocytes in B1 Box-treated EBs were found at Day 21.These 
data suggested that B1 and B1 Dox-treated EBs might acquire atrial cardiac fate.  
Recent study has shown that lentiviral delivery of Cx43 ectopic expression in 
myocardial scar area resulted in increased conduction velocities in the infarct and its border 
zone and during long-time anti-ventricular tachycardia protection [158]. Optical mapping 
of hearts transduced by a Cx43 overexpression lentivirus revealed enhanced conduction 
velocity within the scar, indicating Cx43-mediated electrical coupling between myocytes 
and myofibroblasts. The Cx43 protein expression in myofibroblast surrounding the 
myocytes is unknown. Further experiments need to test this assumption. This is another 
explanation why B1 Dox-treated EBs beats much faster than B1 untreated EBs. 
Furthermore, targeted mutation of Mef2c, downstream of MAP3K7/TAK1, resulted in a 
small left ventricle and complete loss of the right ventricle. Tbx5 was normally expressed 
throughout cardiac crescent but become restricted to sinoatrial region during linear heart 
tube formation. In Mef2c-/- embryos, Tbx5 was ectopically and anteriorly expressed in the 
primitive Mef2c-/- ventricle [159]. 
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Cardiac cells differentiated from Tbx5-overexpression B1 cell line did activated 
enhanced expression of Shox2 and HCN4, however there was no significant difference of 
HCN4 or Shox2 positive population among R1, B1, B1 Dox-treated cardiac cells as 
assessed by ICC. Due to RNA analysis from whole EBs, including cardiomyocytes and 
non-cardiomyocytes, ICC staining only focused on authentic myocytes. This means 
untargeted HCN4 and Shox2 ectopic expression in non-myocytes.  
In summary, Tbx5 is required for cardiac formation generally and is sufficient to  
activate Shox2, Tbx3, Tbx18 and HCN4 transcripts but its expression alone does not 
inhibits Nkx2.5 and Cx43 transcripts. Together these data suggest that Tbx5 cannot activate 







Fig 8.3. Beat Data and Tbx5 transcripts at Day 19 and Day 21 and subtype of 
cardiomyocytes at Day 21. Fig 8.3A. Using MATLAB automation to calculate cardiac 
beats of R1, B1 and B1 Dox-treated EBs at Day 19 and Day 21. Fig 8.3B. The relative 
Tbx5 transcripts among R1, B1 and B1 Dox-treated EBs by qRT-PCR. Data represent 
means ± standard error of 6 independent experiments. Statistical significance was 
determined by unpaired, two-tailed t-test. *p<0.05, ***p<0.001, ****p<0.0001. 
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Fig 8.4. The relative transcripts of R1, B1, B1 Dox-treated EBs at Day 21. MAP3K7/TAK1, 
Tbx5, Shox2, Tbx3, Tbx18,  HCN4, Nkx2.5, Isl1 and Cx43 transcription were assessed by 
qRT-PCR. Data represent means ± standard error of 6 independent experiments, 
normalized to B1. Statistical significance was determined by unpaired, two-tailed t-test. 




Fig 8.5. The subtype of cardiomyocytes of R1, MAP3K7/TAK1 overexpressing, B1, B1 
Dox-treated EBs at Day 21. The percentage of HCN4, Shox2 and Cx43 positive 
cardiomyoctes among all cardiomyocytes were analyzed by ICC. Data represent means ± 
standard error of 3 independent experiments. Statistical significance was determined by 
unpaired, two-tailed t-test. *p<0.05, **p<0.01, ***p<0.001. 
 
Fig 8.6. Sufficient expression of Tbx5 activates Shox2, Isl1, Tbx3, Tbx18 and HCN4 







In the field of regenerative medicine, protocols for lineage specific differentiation 
of cardiomyocytes have promising applications. At first, they will provide the tools to find 
out new markers for SAN fate during differentiation. Second, these well-characterized 
cardiac cells could be used as a basis for pharmacological screening on pacemaker cells 
especially derived from patient-specific iPS cells. This will allow us to test the effect of 
new designed drugs on pacemaker cells. Finally, these cells could serve as the basis for 
biological pacemaker development. Unlike skin or skeleton muscle, adult mammal hearts 
have little or no capability to regenerate themselves after myocardial infarction. 
Furthermore, myocardial infarction causes the formation of apoptotic and necrotic 
myocytes that would be replaced by myofibroblasts and scar tissue in the end. The SAN 
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